Jahanzeb 06/15 1 Citizenship USA Current Positions Professor of Clinical Medicine, Hematology-Oncology Medical Director, USylvester Deerfield Beach Associate Director of Community Outreach Positions Recently Held: 07/08 – 04/10 Medical Director, Lynn Comprehensive Cancer Center West, Boca Raton, Florida 08/02 – 06/08 Chief – Division of Hematology/Oncology, University of Tennessee College of Medicine Memphis, TN 09/05 – 06/08 Fellowship Program Director Hematology Oncology Division, University of Tennessee 12/02 – 06/08 Van Vleet Endowed Professor of Medical Oncology, University of Tennessee Health Science Center, Memphis, Tennessee Undergraduate Education: 4/74 – 9/79 Cadet College, Hasan Abdal, Punjab, Pakistan High School & Pre Med, F.Sc 9/79 10/79 – 5/80 Preparing for medical school Professional Education: 06/80 – 06/86 Medical School: King Edward Medical College, University of Punjab Lahore, Pakistan, MBBS (MD) Completed 6/86 01/85 – 11/86 Rotating Internship & Clinical Clerkship, Mayo Hospital & University of Punjab, Lahore, Pakistan 11/86 – 06/87 Left for the United States in 11/86 and started applying for residencies; also prepared for FLEX taken in 6/87 CURRICULUM VITAE Mohammad Jahanzeb, MD, FACP University of Miami Sylvester Comprehensive Cancer Center 1192 E Newport Center Drive, Suite 215 Deerfield Beach, FL Phone: 954-698-3665 [email protected]
Transcript
Jahanzeb
06/15
1
Citizenship USA Current Positions Professor of Clinical Medicine, Hematology-Oncology
Medical Director, USylvester Deerfield Beach Associate Director of Community Outreach
Positions Recently Held: 07/08 – 04/10 Medical Director, Lynn Comprehensive Cancer Center West, Boca Raton, Florida 08/02 – 06/08 Chief – Division of Hematology/Oncology, University of Tennessee College of Medicine Memphis, TN 09/05 – 06/08 Fellowship Program Director Hematology Oncology Division, University of Tennessee 12/02 – 06/08 Van Vleet Endowed Professor of Medical Oncology, University of Tennessee Health Science Center, Memphis, Tennessee Undergraduate Education: 4/74 – 9/79 Cadet College, Hasan Abdal, Punjab, Pakistan
High School & Pre Med, F.Sc 9/79
10/79 – 5/80 Preparing for medical school
Professional Education: 06/80 – 06/86 Medical School: King Edward Medical College, University of
Punjab Lahore, Pakistan, MBBS (MD) Completed 6/86 01/85 – 11/86 Rotating Internship & Clinical Clerkship, Mayo Hospital & University of Punjab, Lahore, Pakistan 11/86 – 06/87 Left for the United States in 11/86 and started applying for
residencies; also prepared for FLEX taken in 6/87
CURRICULUM VITAE
Mohammad Jahanzeb, MD, FACP University of Miami
Sylvester Comprehensive Cancer Center 1192 E Newport Center Drive, Suite 215
Post Graduate Training United States: 07/87 – 06/88 Internship: New Britain General Hospital, University of CT,
Department of Internal Medicine, New Britain, CT Internal Medicine, Completed 6/88 07/88 – 06/90 Residency: New Britain General Hospital, University of CT,
Department of Internal Medicine, New Britain, CT Internal Medicine, Completed 6/90 07/90 – 06/93 Fellowship: Washington University, Barnes Jewish Hospital Dept. of
Internal Medicine, Division or Hematology / Oncology, St. Louis, MO
07/92 – 06/93 Instructor/ Senior Fellow: Division of Hematology / Oncology, Washington University Honors / Awards: Castle Connolly Top Doctors in America 2010-2013 Best Doctors in America 2011 Best Doctors in America 2007-2008 Castle Connolly Medical Best Doctors in America 2006 Gold Medal Award KEMCAANA 2006 NCCN Board of Producers Award 2008 Silver Medal in Final Professional M.B.B.S. (MD) National Talent Scholarship throughout medical school Leadership / Management Training: Wharton Executive Leadership Program, September 2006 Alliance for Academic Internal Medicine (AAIM) Executive Leadership Program, July 2007 American Board Certification: 11/90 American Board of Internal Medicine (133053) 11/93 American Board of Internal Medicine, subspecialty - Medical Oncology (133053) 11/94 American Board of Internal Medicine, subspecialty - Hematology (133053) 11/03 American Board of Internal Medicine, subspecialties of Hematology and Oncology – Recertification – Medical Oncology valid thru 2013; Hematology valid thru 2015 Licensure: Date Issued Status Expiration Date Pennsylvania - # MD-041064-L 08/17/88 Inactive 12/31/90 Connecticut - #030101 07/07/89 Inactive 06/30/93 Missouri - #00607780 12/10/90 Active 01/31/16 Florida - #ME 68929 08/03/95 Active 01/31/16 Tennessee – MD0000036771 08/02/02 Inactive 06/30/08 Mississippi – 17856 11/18/02 Inactive 06/30/08 Arkansas – E-3595 02/07/03 Inactive 06/30/08
Jahanzeb
06/15
3
Society Memberships: American Association for Professors of Medicine (AAPM) American Association for Cancer Research (AACR) American Society of Clinical Oncology (ASCO) American College of International Physicians - Life Fellow 1997 American College of Physicians (ACP) – Fellow since April 1997 American Society of Internal Medicine (ASIM) - Fellow American Association for Advancement of Science International Association for the Study of Lung Cancer (IASLC) Association of Pakistani Physicians of North America (APPNA) – Life Member King Edward Medical College Alumni Association of North America (KEMCAANA) – Life Member, President Elect 2003, President 2004 Florida Society of Clinical Oncology (FLASCO) Southwest Oncology Group (Institutional Principal Investigator) 2003-2008 Tennessee Medical Association (now lapsed) Cancer and Leukemia Group B (now lapsed) Hoosier Oncology Group (now lapsed) Missouri Society of Clinical Oncology (now lapsed) American Society of Hematology (ASH) (now lapsed) American Medical Association (AMA) (now lapsed) Palm Beach County Medical Society (now lapsed) Broward County Medical Association (now lapsed) University Appointments: 08/10 – Present Professor of Clinical Medicine, University of Miami Miller School of Medicine, Department of Medicine, Division of Hematology/Oncology Medical Director, University of Miami Miller School of Medicine Sylvester Comprehensive Cancer Center, Deerfield Bch Associate Director of Community Outreach, Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine 07/08 – 07/10 Professor of Medicine, University of Tennessee 09/05 – 06/08 Fellowship Program Director, University of Tennessee, Hematology Oncology Division 08/02 – 06/08 Division Chief - Hematology/Oncology, University of Tennessee Hematology/Oncology Memphis, TN 12/02 – 06/08 Van Vleet Endowed Professor of Medical Oncology, University of Tennessee Health Science Center, Memphis, Tennessee 08/02 – 06/08 Associate Professor of Medicine, University of Tennessee College of Medicine 08/04 – 09/05 Interim Director, University of Tennessee Cancer Institute 08/02 – 2003 Planning Director, P-20 Grant (NCI Designation Planning Grant)
Jahanzeb
06/15
4
06/00 – 08/02 Assistant Professor, Biomedical Research, Florida Atlantic University, Boca Raton, Florida 07/93 – 09/95 Assistant Professor of Medicine, Division of Medical Oncology Washington University School of Medicine, St. Louis, Missouri 07/92 – 06/93 Clinical Instructor of Medicine, Division of Medical Oncology Washington University School of Medicine, St. Louis, MO
Medical Student Teaching Experience: 04/14 – Present Lung Cancer Lecture, Miller School M2, Miami, FL 08/05 – 06/08 Pediatric Oncology Education (POE), St. Jude Children’s Research Hospital, Memphis, TN 09/05 – 06/08 Master Clinicians for DRS Course to M1 students, University of Tennessee Health Science
Center, Memphis, TN 10/04 – 10/09 Molecular Basis of Disease to 2nd year student residents and fellows, University of Tennessee
Health Science Center, Memphis, TN 11/03 – 06/08 CPC to 2nd year student residents and fellows, University of Tennessee Health Science Center,
Memphis, TN 10/03 – 06/08 Internal Medicine Core Curriculum Lectures. Teaching to residents and medical students,
University of Tennessee Health Science Center, Memphis, TN 08/02 – 02/05 Teaching hematology module to 2nd year student residents and fellows. Teaching in wards and
clinic. 09/93 – 12/93 Taught "Introduction to Clinical Medicine" course to second-year medical students Washington University School of Medicine, St. Louis, MO 07/90 – 09/95 Participated in teaching Hematology Lab course to second year medical students at Washington University School of Medicine, St. Louis, MO 07/90 – 09/95 Hematology / Oncology Grand Rounds at Washington University - presented grand rounds on twenty different clinical topics over the course of 5 years
Fellows Trained:
01/15- present Sean Warsch, MD
07/07 _ 06/08 Krishna Alluri, M.D.
07/07 – 06/08 Claudia Paba, M.D.
07/07 – 06/08 Andrew Schreiber, M.D.
08/06 – 06/08 Shehzad Azmi, M.D.
07/06 – 06/08 Saira Ahmed, M.D.
07/06 – 06/08 Josh McFarland, M.D.
01/06 – 06/08 Salil Goorha, M.D.
07/05 – 06/08 Jeffrey Allen, M.D.
Jahanzeb
06/15
5
07/05 – 06/08 Gregory Franz, M.D.
07/05 – 06/08 Arshad Husain, M.D.
07/04 – 06/07 Jasgit Sachdev, M.D.
07/04 – 06/07 Sarah Waheed, M.D.
07/03 – 06/06 Sal Vasireddy, M.D.
07/03 – 06/06 Naveed Aslam, M.D.
07/03 – 06/06 Brian McClune, M.D.
01/02 – 12/05 Sonia Benn, M.D.
08/02 – 06/05 Birendra Kumar, M.D.
08/02 – 06/04 James Peyton, M.D.
08/02 – 06/03 Arun Bhandari, M.D.
08/02 – 06/03 Sead Beganovic, M.D.
08/02 – 06/03 Khaleel Ashraf, M.D.
Residents / Medical Students Mentored:
2015 Jennifer M Schwenk
2015 Jason Heffley
2015 Anthony D’Andrea
2015 Jacquelyne Anthony
2014 Ali Khan
2014 Caitlin Hodge
2008 William Rogers
2008 Austin Mackens
2008 Ryan Dougherty
2008 Jason Booton
2008 Justin Marlar
2008 Annie Naik
2008 Andy Patrick
2007 Amna Khattak
2007 Muhammad Raza
2007 Nicholas Newsom
2007 Kevin Walls
2007 Allison Chesser
2007 Muhammad Mirza
2007 Stephen Snell
2007 Lee Sanders
2007 Stephanie Grissom
2007 Elizabeth Hinds
2006 Gautam Jha
2006 Aron Chary
2005 Jessica Snyder
2004 Stacy Jean Brown
2004 Erinn Michelle Myers
2004 Marion Lee Sanders
Jahanzeb
06/15
6
Research Mentorship with Fellows
1. McFarlane J, “Contribution of positive renal vein margin to relapse risk in renal cell cancer”. 2. Azmi S, “Hypersensitivity of Cetuximab: Is there an Association with Race, Region or both?” 3. Paba C, “Empiric dose reduction of Pegfilgrastim in breast cancer patients receiving cytotoxic chemotherapy.” 4. Franz G, “Patterns of PET/CT scan use in patients with advanced Non-Small Cell Lung Cancer (NSCLC).” 5. Schreiber A, “Serial measurements of quality measures using the quality oncology practie initiative (QOPI) by
oncology trainees (fellows) at a single institution.” 6. Sachdev J, “A multicenter phase II trial of carboplatin, vinorelbine, and trastuzumab in previously untreated
patients with HER2 positive metastatic breast cancer.” 7. Waheed S, “Empiric dose reduction of pedfilgrastim in breast cancer patients receiving cytotoxic
chemotherapy.” 8. Peyton J, “Low utility of bone marrow biopsy and aspirate for ruling out malignancy as a cause for FUO in HIV
patients.”
Clinical Research Leadership Positions & Activities (10/95 - present) 07/08 – 04/10 Institutional Principle Investigator, Southwest Oncology Group, Lynn Regional cancer Center
West, Boca Raton, FL 04/03 – 06/08 Institutional Principal Investigator, Southwest Oncology Group, University of Tennessee 08/02 – 06/08 Director of Research, University of Tennessee Cancer Institute Memphis, Tennessee 08/02 – 09/05 Planning Director, University of Tennessee Cancer Institute (submitted P-20 1/03) 04/97 – 08/02 Cancer Center Research Director, Comprehensive Cancer Center, Boca Raton, Florida 01/00 – 08/02 Medical Director, Eugene M. & Christine E. Lynn Clinical Research Center Boca Raton Regional, Boca Raton, Florida 10/95 – 08/02 Co-Chairman, Lung Committee, Salick Healthcare, Inc., Oversight of Clinical Research in Palm Beach County for CCRGI
Jahanzeb
06/15
7
Institutional Principal Investigator Currently Open Trials at University of Miami: BO 28984: RANDOMIZED, MULTICENTER, PHASE III, OPEN-LABEL STUDY OF ALECTINIB VERSUS CRIZOTINIB IN TREATMENT-NAÏVE ANAPLASTIC LYMPHOMA KINASE-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER C-1686-008: A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)
9090-14: A Randomized, Phase 3 Study of Ganetespib in Combination with Docetaxel versus Docetaxel Alone in
Patients with Advanced Non-Small-Cell Lung Adenocarcinoma
SO-BCA002: A Pilot Study Utilizing Proteomic and Genomic Profiling by Reverse Phase Protein Microarray (RPMA), IHC Analysis, RNA-Seq, and Exome Sequencing of Patients’ Tumors to Find Potential Targets and Select Treatments for Patients with Metastatic Breast Cancer
ML 28257: SystHERS:An Observational Cohort Study of Treatment Patterns and Outcomes in Patients with HER2
Positive Metastatic Breast Cancer
SWOG 1400 1400A, 1400B, 1400C, 1400D, 1400E: Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer Institutional Principal Investigator Recent Trials in Boca Raton: E 5103: A Double Blind Phase III Trial of doxorubicin and Cyclophospamide followed by Paclitaxel with
Bevacuzumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
NR001-03: Registration Phase III Study of Lucanix™ (Belagenpumatucel-L) in Advanced Non-small Cell Lung
Cancer: An International Multicenter, Randomized, Double-blinded, Placebo-controlled Study of Lucanix™ Maintenance Therapy for Stages III/IV NSCLC Subjects Who Have Responded to or Have Stable Disease Following One Regimen of Front-line, Platinum-based Combination Chemotherapy (PENDING OPENING)
OXC401-216: A Phase II Study to Assess the Safety and Efficacy of the Combination of Carboplatin, Paclitaxel
and Bevacizumab ± CA4P in Subjects with Chemotherapy Naive Stage IIIB/IV Non-Squamous Cell Histology Non-Small Cell Lung Cancer (NSCLC)
A7471017: A Phase 2, Open-Label Trial of PF-00299804 in Untreated Advanced Adenocarcinoma of the
Lung in Never or Former Light Smokers (Pending Opening) S0429: A Pilot (Phase I) Study of Weekly Docetaxel and Cetuximab Chemo radiation for Poor Risk Stage
III Non-Small Cell Lung Cancer BRE 01-08: Neoadjuvant Weekly nap-paclitaxel (Abraxane®) Plus Carboplatin Followed by Doxorubicin Plus
Cyclophosphamide with Bevacizumab Added concurrently to Chemotherapy for Palpable and Operable Triple Negative Invasive Breast Cancer
Jahanzeb
06/15
8
Institutional Principal Investigator of Trials while in Tennessee:
CALGB 40302: Endocrine Therapy With or Without Inhibition of EGF and HER2 Growth Factor Receptors: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial for Postmenopausal Women with Estrogen-Receptor Positive Advanced Breast Cancer
NSABP B-40: A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable
Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered Before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regimens
NSABP B-42: A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in
Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer
PACCT-1: Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized
Options for Treatment: The TAILORx Trial SWOG 0221: Phase III Trial of Continuous Schedule AC + G Vs. Q 2 Week Schedule AC, Followed by
Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High- Risk Node Negative Breast Cancer
SWOG 0226: Phase III Randomized Trial of Anastrozole versus Anastrozole and Fulvestrant as First Line
Therapy for Post-Menopausal Women with Metastatic Breast Cancer SWOG 0307: Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer AVF 3963g-Ribbon 2: A Phase III, Multicenter, Randomized, Placebo-controlled Trial Evaluating the Efficacy
and Safety of Bevacizumab in Combination with Chemotherapy Regimens in Subjects with Previously Treated Metastatic Breast Cancer
AVF 3964g-Ribbon1: A Multicenter, Phase III, Randomized, Placebo-controlled Trial Evaluating the Efficacy
and Safety of Bevacizumab in Combination with Chemotherapy Regimens in Subjects with Previously Untreated Metastatic Breast Cancer
Pfizer 6171077: A Randomized Phase 2 Study of SU011248 versus Standard-of-care for Patients with
Previously Treated, Advanced, Triple Receptor Negative (ER, PR, and HER2) Breast Cancer
SWOG 0230: Phase III Trial of LHRH Analog Administration during Chemotherapy to Reduce Ovarian Failure
Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer Genentech AVF 4057g-SABRE: A Multicenter, Phase II, Randomized, Controlled Trial Evaluating the
Efficacy and Safety of Sunitinib in Combination with Bevacizumab and Paclitaxel in Previously Untreated Patients with Metastatic Breast Cancer
Jahanzeb
06/15
9
Grants / External Support: 12/07 – 07/08 National Comprehensive Cancer Network, “Neoadjuvant Weekly Nab-Paclitaxel Plus
Carboplatin Followed by Doxorubicin Plus Cyclophosphamide with Bvacizumab Added Concurrently to Chemotherapy for Palpable and Operable Triple Negative Invasive Breast Cancer”, $200,460.
10/07 – 2007 OSI730/SR06-941 Efficacy and Safety of Sorafenib in combination with topotinib in
previously treated, advanced Non-Small Cell Lung Cancer Bayer grant $143,000 OSI Grant $102,500,
12/04 – 2007 Phase II Trial of Carboplatin/Navelbine/Herceptin in HER2+ Metastic Breast Cancer; Genentech, $150,000 (P.I.)
11/04 – 2007 REaCHIT; Research, Education and Collaborative Healthcare in Tennessee, $482,000 (P.I.)
10/04 – 03/10 Enhancing Lives Via Information Systems (ELVIS): A Community Network to Reduce Cancer Health Disparities; $3,450,670 (Co-Investigator)
12/02 – 08/04 Phase II Study of Docetaxel Consolidation After Chemo-Radiotherapy of Inoperable Stage III Non-Small Cell Lung Cancer; $522,500; Aventis Pharmaceuticals (P.I.)
09/98 – 06/01 Multicenter Phase II Trial of Weekly Vinorelbine plus Herceptin in Chemonaive Patients with HER-2/neu Positive Metastatic Breast Cancer; $200,000; GlaxoSmithKline/Genentech (P.I.)
06/97 – 12/99 A Multicenter Phase II Trial of Carboplatin and Docetaxel in Previously Untreated Advanced Non-Small Cell Lung Carcinoma; $75,000; Phone-Poulenc Rorer (P.I.)
01/97 – 12/98 Phase I Study of Doxil in Combination with Escalating Doses of Navelbine for the Treatment of Patients with Advanced Malignancies; $30,000; Sequus (P.I.)
01/97 – 12/98 Phase I Study of Doxil in Combination with Escalating Doses of Taxotere for the Treatment of Patients with Advanced Malignancies; $30,000; Sequus (P.I.)
09/96 – 12/98 Peglyated Liposomal Doxorubicin as Second Line Treatment of Advanced Non-Small Cell Carcinoma after Platinum Based Therapy: A Randomized Phase II Trial; $100,000; Sequus (P.I.)
06/96 – 12/98 A Phase I Trial of Vinorelbine and Gemcitabline in Relatively Elderly Patients with Refractory Solid Tumors; $135,000; GlaxoSmithKline, Eli Lilly, Amgen (P.I.)
Completed Clinical Research:
SWOG 0802: A Phase II Trial of AVE0005 (VEGF Trap; Aflibercept) in Patients with Platinum-Treated Extensive Small Cell Lung Cancer
NSABP B-38: A Phase III, Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Node-Positive Breast Cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide Followed by DD Paclitaxel (DD AC -> P); DD AC Followed by DD Paclitaxel Plus Gemcitabine (DD AC -> PG)
BRE-25 A Phase III Study to Compare the Neoadjuvant Administration of Docetaxel and Vinorelbine or
Docetaxel followed by Adriamycin and Cytoxan with all Chemotherapy Administered in a Dose-Dense Fashion to Women with Stage II and Stage III Breast Cancer
Roche: ML 18530 An open-label study of capecitabine (Xeloda®) and docetxel (Taxotere®) as neoadjuvant
treatment for patients with recently diagnosed HER2-neu negative breast cancer, plus trastuzumab (Herceptin®) for HER2-neu positive breast cancer
Jahanzeb
06/15
10
SWOG 0124 Randomized Phase III Trial of Cisplatin and Irinotecan versus Cisplatin and Etoposide in Patients with Extensive Stage Small Cell Lung Cancer
Glaxo Smith Kline- KSP20007 A Phase II, Open-Label Study of SB-715992 in Subjects with Locally Advanced or
Metastatic Platinum-Refractory or Platinum-Sensitive Relapsed Non-Small Cell Lung Cancer (NSCLC
H3074 A Multicenter, Open-Label, Single Arm, Phase II Trial Investigating the Efficacy and Tolerability of
Vinorelbine, Carboplatin and Trastuzumab for the First-Line Treatment of Metastatic Breast Cancer in Women with HER2+Disease
BRE-22 NSABPB-33 - A Randomized, Placebo-Controlled, Double-Blind Trial Evaluating the Effect of Exemestane in Clinical Stage T1-3 N0-1 M0 Postmenopausal Breast Cancer Patients Completing at Least Five Years of Tamoxifen Therapy)
BRE-18 GlaxoSmithKline An Open-Label, Multicenter, Single Arm Phase II Study of Oral GW572016 as Single Agent Therapy in Subjects with Advanced or Metastatic Breast Cancer Who Have Progressed While Receiving Herceptin Containing Regimens
BRE-19 Wyeth 3066A1-204-WW - A Phase 2 Randomized Open-Label Study of Letrozole in Combination with Two Dose Levels and Schedules of Oral CCI-779, or Letrozole Alone in Postmenopausal Women with Locally Advanced or Metastatic Breast Cancer
BRE-20 SWOG NSABP B-34 – A Clinical Trial Comparing Adjuvant Clodronate Therapy vs Placebo in Early-Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Tamoxifen or No Therapy
BRE-21 SWOG S9630 – A Randomized Comparison of Medroxyprogesterone Acetate (MPA) and Observation for Prevention of Endometrial Pathology in Postmenopausal Breast
BRE-23 SWOG NSABP B-30 – A Three-Arm Randomized Trial to Compare Adjuvant Adrimycin and Cyclophosphamide Followed by Taxotere (AC-T) Adrimycin and Taxotere (AT) and Adrimycin, Taxotere, and Cyclophosphamide (ATC) in Breast Cancer Patients with Positive Axillary Lymph Nodes
BRE-24 Pharmacia – Phase II Randomized, Open-Label Study of 2 Schedules of Single-Agent Oral Irinotecan in Patients with Metastatic Breast Cancer Who Have Experienced Failure of Prior Therapy with an Anthracycline, a Taxane and Capecitabine
BRE-26 Genentech – A Multicenter, Open-Label, Single Arm, Phase II Trial Investigating the Efficacy and Tolerability of Vinorelbine, Carboplatin and Trastuzumab for the First-Line Treatment of Metastatic Breast Cancer in Women with HER2+ Disease
LUN-24 OSI Pharmaceuticals – A Phase III, Randomized, Double-Blind, Multicenter Study of the Efficacy of Taxotere® (Docetaxel) in Combination with Aptosyn™ (exisulind) verses Taxotere® (Docetaxel) and Placebo in Non-Small Cell Lung Cancer Patients after Failure of Prior Platinum Based Chemotherapy
LUN-28 SWOG S9900 – A Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Paclitaxel/Carboplatin in Clinical Stage IB, II and Selected IIIA Non-Small Cell Lung Cancer
LUN-30 SWOG S0023 – A phase III trial of cisplatin/etoposide/radiotherapy with consolidation docetaxel followed by maintenance therapy with ZD1839 or placebo in patients with inoperable locally advanced stage III non-small cell lung cancer
LUN-31 (NCIC CTG BR.19): A phase III prospective randomized, double-blind placebo-controlled trial of the epidermal growth factor receptor antagonist, ZD1839 in completely resected primary stage IB, II and IIIA non-small cell lung cancer
PRE-1 SWOG S0002 – Smoking Cessation Intervention for Completely Resected Stage I and Stage II Non-Small Cell Lung Cancer Survivors Who Are Currently Smokers, Phase III
SWOG 0802: A Phase II Trial of AVE0005 (VEGF Trap; Aflibercept) in Patients with Platinum-Treated Extensive
Small Cell Lung Cancer
Jahanzeb
06/15
11
Participated in Pivotal Herceptin trials leading to its FDA approval (see appendix of “Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2”, NEJM, March 15, 2001, vol 344, no 11) Started investigator initiated studies in metastatic breast cancer, during previous employment with Boca Raton Comprehensive Cancer Center Inc. Between 1996 -2002. (An asterisk denotes investigator initiated studies) Options for Breast Cancer Patients: *A Phase II Trial of Vinorelbine and Herceptin Given Weekly for Previously Untreated Metastatic
HER/2 Neu Positive Breast Carcinoma ICRG B1, Proceedings of American Society of Clinical Oncology, May, 2001 (Abst #1986) Final publication The Oncologist, 11/2002
*A Phase II Trial of Docetaxel plus Herceptin as First or Second Line Therapy for Metastatic,
HER/2 Positive Breast Carcinoma ICRG B2 (Closed) Options for Lung Cancer Patients: Developed a new lung cancer research program within CCRGI offering multiple treatment options
to lung cancer patients (see below) with research grants from pharmaceutical companies First Line Treatment Options: Paclitaxel/carboplatin with or without Tarceva (Closed to Accrual) *Taxotere + carboplatin (Published, Anticancer Research 2004, 24: 1239-1242) or Any Phase I Trials *Gemzar + Navelbine (Glaxo Wellcome/Lilly) (completed accrual, reported at ASCO, May 1999, Abst #897A) *Doxil + Taxotere (Sequus) (Completed accrual, reported at ASCO, May 1999, Abst. #820) *Doxil + Navelbine (Sequus) (Completed accrual, reported at ASCO, May 1999, Abst. #827) Cisplatin VP16 vs cisplatin + tirapazamine (closed)
RPR 326 – A multicenter randomized trial comparing Taxotere/cisplatin vs. Taxotere/Carboplatin vs. cisplatin/vinorelbine (closed to accrual, reported at ASCO 2001)
Oral vs. IV Navelbine (closed)
Taxol + carboplatin ± Iressa (closed) Aventis 203 – Taxotere/CPT-11 weekly x 4 with 2 week rest (Closed)
Post chemotherapy (within 60 days) for responders and stable patients Tegretin (vit. A analog) Vs. Placebo, (Ligand) (closed)
Second Line Treatment Options (platinum failures):
Jahanzeb
06/15
12
Cell Pathways #208 – Weekly Taxotere ± Aptosyn (Closed) *Doxil Weekly or Q 4 weeks (Sequus) (completed accrual, reported at ASCO, May 1999, Abst. #2004) AstraZeneca – Expanded Access IRESSA Program (closed) ZD0473 in Platinum Failures (Closed)
Patients with Stage IIIA or Selected IIIB Lung Cancer:
Minimal residual disease after treatment with any reasonable combination of chemotherapy, radiation and surgery:
Miramastat vs. Placebo, (Closed) Patients with Stage I, II, or III Completely Resected Lung Cancer:
*Paclitaxel/carboplatin/radiation followed by weekly or q3 weeks docetaxel consolidation International Adjuvant Lung Trial, The New England Journal of Medicine, Vol. 350, No. 4, January
22, 2004; 351-360. Observation vs. cisplatin + vinorelbine (+XRT for N2 disease) Resectable Stage III with mediastinoscopically proven N2 disease: TAX 711 Neoadjuvant study, cisplatin/Taxotere x 3 cycles followed by surgery followed by
radiation therapy (ASCO, June 2003, Abst. #2652) (Closed) Small cell lung cancer (extensive stage after CR or PR to chemotherapy): Bayer MMPI randomized placebo-controlled trial (closed to accrual) ZD0473 in platinum failures (closed)
Hospital Appointments: 04/10 _Present University of Miami Hospital and Clinics (Sylvester) 07/08 – Present Boca Raton Regional Hospital, Boca Raton, FL 08/02 – 07/08 Methodist Healthcare University Hospital, Memphis, TN 08/02 – 07/08 Methodist Healthcare North, Memphis, TN 08/02 – 07/08 Methodist Healthcare Germantown, Germantown, TN 08/02 – 07/08 Methodist Healthcare Desoto, Southaven, MS 08/02 – 07/08 Regional Medical Center at Memphis, TN 08/02 – 07/08 Veterans Affairs Medical Center, Memphis, TN 08/02 – 07/08 Baptist Memorial Hospital East, Memphis, TN 08/02 – 07/08 Baptist Women’s Hospital, Memphis, TN 08/02 – 07/08 Baptist DeSoto Hospital, Southaven, MS 08/02 – 07/08 St. Francis Hospital, Memphis, TN 11/02 – 07/08 St. Francis Bartlett Hospital, Bartlett, TN 07/07 – 07/08 St. Bernards Medical Center, Jonesboro, AR 08/02 – 09/04 University of Tennessee Bowld Hospital, Memphis, TN 01/00 – 06/08 Staff Physician and Medical Director, Eugene M. & Christine E. Lynn Clinical Research Center, Boca Raton Regional Hospital, Boca Raton, FL 01/00 – 08/02 West Boca Medical Center, Boca Raton, FL
Jahanzeb
06/15
13
01/00 – 08/02 Delray Medical Center, Delray Beach, FL 01/00 – 08/02 JFK Medical Center, Lake Worth, FL 01/00 – 08/02 Bethesda Memorial Hospital, Boynton Beach, FL 07/93 – 09/95 Staff Physician, John Cochran Veterans Administration Hospital, St. Louis, MO 07/93 – 09/95 Attending Physician, Jewish Hospital, St. Louis, MO 07/93 – 09/95 Attending Physician, Barnes Hospital, St. Louis, MO
Editorial Appointments: 2013 - Present Chief Editor for Journal of Cancer and Allied Specialties 2011 – 2013 Chief Editor for Managed Care in Oncology 01/08 – Present Editorial Board for Journal of Clinical Oncology 01/99 – 06/05 Editorial Board for Clinical Lung Cancer 01/02 – 2004 Editorial Board for CURE 06/97 – 12/00 Editor-in-Chief for Navelbine Update / Pipeline News - A Quarterly Newsletter of Glaxo Welcome for Navelbine Investigators Ad-hoc Reviewer for Journals: Clinical Cancer Investigation Journal of Clinical Oncology Lung Cancer (Journal of International Association for the Study of Lung Cancer) Cancer CA: A Cancer Journal for Clinicians Clinical Lung Cancer Chemotherapy Cancer Investigation American Journal of Cancer Caring4Cancer Tumor Future Oncology Future Medicine National Committee Memberships and Offices Held: SystHERs Steering Committee- 2015 FLASCO Board of Directors- 2015 FLASCO Program Committee- Chairman 2015 ASCO Quality Oncology Practice Initiative (QOPI) Chair Elect- (2014 to present) ASCO Breast Cancer Guidelines Panel for HR+ Patients (2012 to present) ASCO Quality Oncology Practice Initiative (QOPI) Quality Measures Development Committee (2006-Present) ASCO QOPI Alpha Group (2003 – Present) ASCO Breast Cancer Guidelines Panel (2012) Adhoc Committee Information Technology (2012) NCCN REMS Working Group (2010) ICORE Advisory Board (2009 – 2012) NCCN ARIES Lung Cancer Steering Committee (2007-Present) Board of Directors, National Comprehensive Cancer Network (NCCN) (2003 – 2009) Guidelines Steering Committee, NCCN (2002 – 2009) CME Committee, NCCN 2007 – 2009) Lung Cancer Expert Panel, NCCN (2003 – 2013) Breast Cancer Expert Panel, NCCN (2003– 2009)
Jahanzeb
06/15
14
Research Investigators Steering Committee, NCCN (2004 –2009) Venous Thromboembolism Panel, NCCN (2004 – 2008) Lung Committee, Southwest Oncology Group (2003 – 2010) Breast Committee, Southwest Oncology Group (2003 – 2010) Adjuvant Panel, Breast Cancer, NCCN (2004 – 2009) Elderly Breast Cancer Task Force, NCCN (2007) HER2 Testing Task Force, NCCN (2006) ASCO’s Medical Oncology In-Training Examination Item Harvesting Committee (2007) Venous Thromboembolism Panel, American Society of Clinical Oncology (ASCO) (2006) Executive Committee Member, IACA (2007 – 2012) Research and Education Committee, Association of Pakistani Physicians of North America (APPNA) (2006-Present); Chair for 2014 Resource Development Committee, APPNA (2002) President, King Edward Medical College Alumni Association of North America (KEMCAANA) (2004) President Elect, KEMCAANA (2003) Secretary, KEMCAANA (2002) Treasurer, KEMCAANA (2001) Local Committee/ Regional Memberships / Task Forces: Rotary Club- Present CME Committee Boca Raton Regional Hospital (2008 – 2010) Cancer Committee – Boca Raton Regional Hospital (2008 - Present) Gilda’s Club of South Florida (2008 - Present) ACS Hope Lodge Foundation Committee (June 2006 – June 2008) Central Biomedical District, Memphis, TN (March 2003 – June 2008) Methodist Healthcare Foundation Board, Memphis, TN (March 2003 – June 2007) Executive Committee, University of Tennessee Cancer Institute, Memphis, TN (Aug. 2002 – June 2004) Clinical Committee, University of Tennessee Cancer Institute, Memphis, TN (Aug. 2002 – June 2004) Transition Committee, University of Tennessee-Methodist Healthcare, Memphis, TN (2002 – 2003) Steering Committee, University of Tennessee Cancer Institute, Memphis, TN (2002 – 2003) Cancer Care Committee, Boca Raton Regional Hospital, Boca Raton, FL (1997 – 2002) Pharmacy and Therapeutics Committee, Boca Raton Regional Hospital, Boca Raton, FL (2000 – 2002) CME Committee, Boca Raton Regional Hospital, Boca Raton, FL (2000 – 2002, and 2008-2009) Cancer Care Committee, JFK Medical Center, Atlantis, FL (1995 - 2000) Advisory Board, Wellness Community, Boca Raton, FL (2000 – 2002) Cancer Care Committee, VA Hospital, St. Louis, MO (1993 - 1995)
University of Tennessee Committees Research Membership Committee for Internal Medicine Resident (July 2007 – June 2008) UTCI Planning Committee (2002-2005) UTCI Steering Committee (2002-2005) UTCI Focus Group (2002-2005) UTCI Cancer Center Director Search Committee (2002-2005) UTCI Membership Committee (2002-2005) UTCI Statewide Planning Committee (2002-2005) UTCI Community Advisory Board (2002-2005) University of Miami Committees Quality and Value Committee, University of Miami- Sylvester Comprehensive Cancer Center (2010) Chair, Sylvester Research Acceleration Grant Committee
Jahanzeb
06/15
15
UM Sylvester End of Life Task Force Breast Cancer SDG member Lung SDG Interim Chair 07/2012 - 07/2014 UM Cancer service Line Governance Council (2008-2011) Community Service: 2015- Dolphins Cycling Challenge, “DCC Heavy Hitter” 2013- Dolphins Cycling Challenge, “DCC Heavy Hitter” 2009 – Susan G Komen for the Cure South Florida “Knowledge is the Power of Pink” interactive panel 2008 – Gilda’s Club – Professional Healthcare Council 2007 – Methodist Hospice Fundraising Campaign Committee 2007 – ACS Hope Lodge Capital Campaign Committee 2007 – East Memphis Rotary Club, “Cancer and Its Treatment: Future is Here Now” 2006 – Cancer Talk Live Forum, Peabody Hotel 2004 – Collierville Rotary Club, “An Overview of UTCI” 2004 – East Memphis Rotary Club, “An Overview of UTCI” 2004 – Memphis Kwanis Club, “An Overview of UTCI” 2004 – Medical Education and Research Institute, “The Value of a Multi-disciplinary Breast Cancer Clinic” 2003 – Memphis Rotary Club, “An Overview of UTCI” 2003 – Chancellor’s Rountable, “Rationale of a Statewide UTCI” 2003 – University of Tennessee Board of Trustees, Rationale of a Statewide UTCI” 2002 – Wellness Community of Boca Raton
Course Directorship of International, National and Regional CME Symposia Initiated, organized, and directed (including fundraising) the following CME symposia as Program Chair / Course Director: Annual Asia & Middle East Guidelines in Oncology Symposia: 04/09 2nd Annual Asia & Middle East Guidelines in Oncology Congress, Abu Dhabi, UAE 02/08 1st Annual Asia & Middle East Guidelines in Oncology Symposium, “Decision Making in
Oncology: Evidence & Consensus”, Al Ain, UAE Annual Palm Beach Cancer Symposia: 8/14 37th Association of Physician of Pakistan Descent of North America (APPNA), CME, National Harbor,
Washington D.C.
04/11 12th Annual Palm Beach Cancer Symposium, “Personalizing Care in the Era of Genomic Tests and Targeted Therapies”, 16 speakers, 2 days, Fort Lauderdale, FL 04/09 11th Annual Palm Beach Cancer Symposium, “Personalized Medicine in the Era of Targeted Therapy”, 18
Speakers, 2 days, Hollywood, FL 04/08 10th Annual Palm Beach Cancer Symposium, “Practical Issues in Patient Care”, Palm Beach, FL
Jahanzeb
06/15
16
(Planning) 15 speakers, 2 days, Palm Beach, FL 04/07 9th Annual Palm Beach Cancer Symposium, “Tailoring Treatment with Targeted Therapies”, 14 speakers,
2 days, Palm Beach, FL 04/06 8th Annual Palm Beach Cancer Symposium, “Shifting Paradigms of Treatment” 13 speakers, 2 days,
Palm Beach, FL 04/05 7th Annual Palm Beach Cancer Symposium, “Combined Modality Therapy of Common Malignancies” 14
speakers, 2 days, Palm Beach, FL 04/04 6th Annual Palm Beach Cancer Symposium, “A Quickening Pace of Progress” – 12 speakers, 2 days,
Palm Beach, FL 03/03 5th Annual Palm Beach Cancer Symposium, “Emerging Paradigms in Cancer Care” – 16 speakers, 2
days, Delray Beach, FL 03/02 4th Annual Palm Beach Cancer Symposium, “Moving Beyond the Ordinary” - 12 speakers, 2 days, Delray
Beach, FL 03/01 3rd Annual Palm Beach Cancer Symposium, “Filling in the Gaps” - 14 speakers, 2 days, Delray Beach, FL 03/00 2nd Annual Palm Beach Cancer Symposium, “Cancer Care in the Community” - 13 speakers, 2 days,
Pompano Beach, FL 02/99 1st Annual Palm Beach Cancer Symposium, “Multi-modality Management of Common Malignancies” - 18
speakers, 3 days, Boca Raton, FL
Annual Mid-South Cancer Symposia:
11/08 6th Annual Mid-South Cancer Symposium, “Multi Modality Therapies of Common Solid Tumors – Focus on Head & Neck Cancer
10/07 5th Annual Mid-South Cancer Symposium, “Focus on Thoracic Oncology”, 11 speakers, 1 day, Memphis, TN
Other Programs: 06/04 Co-Director, CME Course, “Old Problems, New Solutions”, APPNA Annual Convention,
Washington, DC 11/97 “Lung Cancer in the New Millennium” - 6 speakers, 1 day, Boca Raton, FL 97 - 02 Monthly CME accredited city-wide tumor board 08/95 CME meeting for Association of Pakistani Physicians of North America (APPNA), St. Louis, MO Extracurricular Activities:
Writer of prose and poetry, publications in various magazines and broadcasts on Radio Pakistan, Lahore
Contributed several pieces of prose and poetry to journals of APPNA and KEMCANNA
1. Goiania, Brazil, May 14- May 16, 2015, “Triple negative tumors: is there evidence for platin in adjuvant
therapy”, “Advances in the early stage breast cancer adjuvant therapy”, “Breast cancer treatment advances of HER 2 (+) breast cancer”.
2. Goiania, Brazil, May 23 – May 25, 2013, “Evaluation of Genomic Platforms in Invasive Breast Cancer: A Review of Clinical Validation Evidence and Two Head-to-Head Clinical Utility Studies”. “Management of Bone Metastasis in Breast Cancer”.
3. Moscow, Russia, December 19 – December 23, 2012, “Challenges in Adaptation and Adoption of the NCCN Guidelines”
4. Lahore, Pakistan, November 8 – November 12, 2012, “NCCN Guidelines: The Process of Guideline Development”, “Towards More Personalized Therapy for Non-Small Lung Carcinoma”, “Estimating Risk of Recurrence in Early Stage Breast Cancer”.
5. Salvador, Brazil, October 10 – October 13, 2012, “NCCN” Guidelines Process: International Adaptations”, “Neoadjuvant Chemotherapy in Breast Cancer”.
6. Namibia, South Africa, April 26 – 27, 2012, NCCN 1st Steering Committee Meeting for Sub-Saharan Africa, “NCCN Overview: Guidelines Development and Implementation in the United States”, “NCCN International Initiatives:
7. Doha, Qatar, January 2012, MENA-NCCN Regional Meeting, “Challenges and Opportunities in the International Adaptation of the NCCN Guidelines”
8. Gramado, Brazil, October 2011, ASCO-SBOC Joint Symposium, XVII Brazilian Congress of Clinical Oncology, “Economic Implications of Cancer and Cancer Treatment” “Impact of Guidelines in Clinical Practice”
9. Goiania, Brazil, October 2011, Brazilian Congress Of Mastology, “Breast Conservation after Neoadjuvant
Therapy” “Which Patient Should be Offered Neoadjuvant Therapy” “The State of the Art on the Treatment of HER2 Positive Breast Cancer Patients”
10. Mexico City, Mexico, August 2011, 1st Symposium Treatment with Care, “An Update in Supportive Care Therapies and Breast Cancer Treatments:
11. Amsterdam, The Netherlands, July 2011, 14th World Conference on Lung Cancer – IASLC – “Sarcoma
of Lung”. Discussant for oral abstract session. 12. Rio de Janeiro, Brazil, July 2011, NCCN-GLICO Meeting, Personalized Medicine and Challenges in
Clinical Research. “NCCN Global Initiatives”.
13. Cape Town, South Africa, May 2011, University of Stellenbosch Oncology “NCCN Guidelines in Early Breast Cancer”.
14. Cape Town, South Africa, May 2011, Cape Town Stadium “The Use of Avastin in Breast and Lung Cancer”.
15. Durbin, South Africa, May 2011, Moses Mabhida Stadium “NCCN Guidelines in Early Breast Cancer”.
16. Pietermaritzburg, South Africa, May 2011, “The Use of Avastin in Breast and Lung Cancer”.
Jahanzeb
06/15
18
17. Johannesburg, South Africa, May 2011, FNB Stadium “NCCN Guidelines in Early Breast Cancer” and “The Use of Avastin in Breast and Lung Cancer”.
18. Cape Town, South Africa, May 2011, University of Pretoria, “NCCN Guidelines in Early Breast Cancer”.
19. Berlin, Germany, January 2011, “Debate: It is time to switch to Denosumab in Breast Cancer Patients with Bone Mets”.
20. Antalya, Turkey, November 2010, “Using Gene Signatures in Assigning Adjuvant Therapy; Case Studies”
21. Antalya, Turkey, November 2010, “Clinical Endpoints in Metastatic Breast Cancer”
22. Antalya, Turkey, November 2010, “NCCN Guidelines”
23. Riyadh, Saudi Arabia, “Challenges of Disseminating NCCN Guidelines Worldwide
24. Gramado, Brazil, August 2010 “Antibody Therapy in Breast Cancer”
25. Gramado, Brazil, August 2010 “Genomic Tests in Clinical Practice”
26. Cuernavaca, Mexico, June 2010 “Progression-Free Survival vs. Overall Survival as Endpoints in Metastatic Breast Cancer”
27. Kirenya, Cyprus, May 2010 “ Endpoints in Clinical Oncology Studies”
28. Lima, Peru, April 2010 “Clinical Guidelines, Present and Future in Latin America”
29. Lahore, Pakistan, at Shaukat Khanum Cancer Research Hospital, February 2010 “Recent treatment options in HER2 positive MBC”
30. Lahore, Pakistan, at Shaukat Khanum Cancer Research Hospital, February 2010 “Recent treatment options in HER2 positive MBC”
31. Gujranwala Pakistan, at Inauguration of GINUM (Institute of nuclear medicine) February 2010 “NCCN
Guidelines in NSCLC” 32. Kuwait City, Kuwait, February 2010 “Breast Guideline Sessions”
33. Kuwait City, Kuwait, February 2010 “Breast Guideline Sessions”
34. Kuwait City, Kuwait, February 2010 “Breast Guideline Sessions”
35. Vienna, Austria, January 2010 “Case studies in Lung Cancer”
36. Lahore, Pakistan, November 2009 “Recent Treatment Options in HER2 Neu Metastatic Breast Cancer”
37. Gramado, Brazil, October 2009 “Evidence of Anticancer Properties of Bisphosphonates in the Treatment of Breast Cancer”
38. Gramado, Brazil, October 2009 “role of NCCN Guidelines in Cancer Care”
39. Berlin, Germany, September 2009 ECCO/ESMO “Safety of Bevacizumab (BV) Combined with Chemotherapy in Patients with Non-Squamous Non-Small Cell Lung Cancer (NSCLC): Interim Results from the ARIES Lung Observational Cohort Study”
40. Beirut, Lebanon, May 2009 “Towards Tailored Therapies in Breast Cancer”
41. Doha, Qatar, May 2009 “Towards Tailored Therapies in Breast Cancer”
42. Cairo, Egypt, May 2009 “Guidelines in Treating ErbB2 Positive Breast Cancer”
43. Cairo, Egypt, May 2009 “NCCN Guidelines for Early Breast Cancer”
Jahanzeb
06/15
19
44. Cairo, Egypt, May 2009 “ST. Gallen Updates”
45. Kuwait City, Kuwait, April 2009 “Update on Targeted Therapy for ErbB2 positive breast cancer”
46. Muscat, Oman, April 2009 “Introducing Tykerb, A novel targeted therapy for ErbB2 breast cancer”
47. Abu Dhabi, UAE, April 2009 “Overview of NCCN Lung Cancer Guidelines”
48. San Juan, PR, February 2009, “Focus on the Host and Therapy-Related Toxicities”
49. San Juan, PR, February 2009, “Adjuvant HER-2 directed Therapy: Candidates and Practical Management”
50. Lahore, Pakistan, February 2009, “Systemic Therapy for Node Positive Breast Cancer”
51. Seville, Spain, January 2009, “Identifying Patients iwth Aggressive Solid Tumors who would benefit from Bisphosphonate Therapy”
52. Riyadh, Saudi Arabia, January 2009, “Prognosis, Prediction and Therapy in HR+ Breast Cancer: SABCS Review of Abstracts 53, 57 and 81”
53. Riyadh, Saudi Arabia, January 2009, “Tailoring Targeted Therapies in Breast Cancer”
54. Madrid, Spain, October 2008, “2008 Zenith Day: Focus on Breast Cancer”
55. Sao Paulo, Brazil, August 2008, “Emerging Strategies for Management of Endocrine Responsive Breast Cancer”
56. Rio De Janeiro, Brazil, August 2008, “NCCN Guidelines Discussion”
57. Salvator, Brazil, August 2008, “NCCN Guidelines Discussion”
58. Curitiba, Brazil, August 2008, “NCCN Guidelines Discussion”
59. Dubai, UAE, May, 2008, “Risk of Recurrence in Early Breast Cancer” 60. Dubai, UAE, May, 2008, “Decision Making in Endocrine Therapy for Early Breast Cancer” 61. Beijing, China, March, 2008, “Update on NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell
Lung Cancer” 62. Shanghai, China, March, 2008, “Update on NCCN Clinical Practice Guidelines in Oncology: Non-Small
Cell Lung Cancer” 63. Guangzhou, China, March, 2008, “Update on NCCN Clinical Practice Guidelines in Oncology: Non-Small
Cell Lung Cancer” 64. Tokyo, Japan, January, 2008, “Does ‘shifting gears’ toward recurrent breast cancer exist?” 65. Seoul, South Korea, November, 2007, “NCCN CRAC and Non-Small Cell Lung Cancer Guidelines”
79. Lahore, Pakistan, March, 2005, “How to Publish a Manuscript”, Seventh Shaukat Khanum Memorial Cancer Symposium.
80. Lahore, Pakistan, March, 2005, “Targeted Therapy in the Management of Breast Cancer”, Seventh
Shaukat Khanum Memorial Cancer Symposium.
81. Lahore, Pakistan, December 2004, “Chemotherapy of Early Breast Cancer”, 23rd Annual KEMCAANA Symposia.
82. Rawalpindi, Pakistan, December 2004, “Adjuvant Chemotherapy of Breast Cancer”, Armed Forces
Institute of Pathology.
83. Peshawar, Pakistan, December 2004, “Adjuvant Chemo of Breast Cancer”, Golden Jubilee Celebration, Kayhee Medical College Pakistan, Plenary Session.
84. Jaipur, India, December 2002, NCCN “Lung Cancer Management Guidelines”, National Comprehensive
Cancer Network for India.
85. Multan, Pakistan, December 2002, “Neo Adjuvant in Breast Cancer Chemotherapy”, Educational Symposium Golden Jubilee at Nishtar Medical College
86. Lahore, Pakistan, December, 2002, “Chemotherapy in Breast Cancer”, King Edward Medical College
87. Buenos Aires, Argentina, October 2001, “Present and Future Use of Herceptin in the Treatment of
Breast Cancer,” XI Conference on Breast Cancer, Plenary Conference
88. Buenos Aires, Argentina, October, 2001, “Systemic Treatment of Breast Cancer in Situ,” XI Conference on Breast Cancer Symposium
Jahanzeb
06/15
21
89. Lahore, Pakistan, October, 2000, “Lung Cancer Management in the New Millennium,” Shaukat Khanum
Research Hospital 90. Tokyo, Japan, September, 2000, “Carboplatin and Docetaxel in Previously Untreated Advanced Non-
Small Cell Lung Carcinoma (NSCLC): a Multicenter Phase II Trial,” oral presentation of abstract, IASLC 9th World Conference on Lung Cancer
91. Vancouver, Canada, August, 2000, “Overview of Taxotere in Non-Small Cell Lung Cancer,” Taxotere
Advisory Board Meeting
92. Toronto, Canada, July, 2000, “Overview of Taxotere in Breast Cancer,” Taxotere Advisory Board
93. Rawalpindi, Pakistan, December, 1999, “Neoadjuvant Treatment for Breast Cancer,” Armed Forces Postgraduate Medical Institute
94. Lahore, Pakistan, December, 1999, “Neoadjuvant Treatment for Breast Cancer,” Association of Family
Physicians
95. Lahore, Pakistan, December , 1999, “Update in The Treatment of Non-Small Cell Lung Cancer,” King Edward Medical College Alumni Association of North America
96. Lahore, Pakistan, December, 1999, “Internet in Medicine,” King Edward Medical College Alumni
Association of North America 97. Lahore, Pakistan, December, 1997, “Combined Modality Therapy in Non-Small Cell Lung Cancer,” King
Edward Medical College Alumni Association of North America Annual Winter Symposium
98. Rawalpindi, Pakistan, December 1997, “Combined Modality Therapy in Non-Small Cell Lung Cancer,” Armed Forces Postgraduate Medical Institute
99. Lahore, Pakistan, December 1997, “Management of Locally Advanced Non-Small Cell Lung Cancer,"
Shaukat Khanum Memorial Cancer Hospital and Research Center Annual Meeting of Pakistan Medical Research Society
100. Singapore, July, 1997, “Advances in Treatment of Breast Cancer,” Singapore Society of Oncology
101. Seoul, South Korea, July, 1997, “Role of Navelbine in Breast Cancer Treatment”
102. Pusan, South Korea, July, 1997, “Role of Navelbine in Breast Cancer Treatment”
103. Taegu, South Korea, July, 1997, “Role of Navelbine in Breast Cancer Treatment”
104. Lahore, Pakistan, February, 1997, “Treatment Options for Women with Metastatic Breast Cancer,” Third
annual symposium of Shaukat Khanum Memorial Cancer Hospital
105. Rawalpindi, Pakistan, December, 1994, “Treatment of Early Stage Breast Cancer,” CME conferences in Lahore, Pakistan and Armed Forces Institute of Medical Sciences
106. Rawalpindi, Pakistan, December, 1992, “Role of Chemotherapy in Lung Cancer,” seminar on cancer
therapy in Lahore, Pakistan and Armed Forces Institute of Medical Sciences
Jahanzeb
06/15
22
CME Accredited Lectures as Invited Speaker within the US:
1. Orlando, FL, January 31, 2015, Review and Interpretation of the 2014 San Antonio Breast Cancer Symposium
2. Tampa, FL, November 2014, “FLASCO Fall Meeting ”
3. Memphis, TN, September 2014, The Inaugural Raza A. Dilawari Endowed Distinguished Visiting Professorship
4. Oklahoma, August 2014, OSCO/OU Stephenson Cancer Center ASCO Review 5. Kansas City, August 2014, The University of Kansas Medical Center, ASCO review 6. New Orleans, July 2014, 9th Annual New Orleans Summer Cancer Meeting
7. Chicago, IL, May 2014 “American Society Clinical Oncology Conference”
8. Jacksonville, FL, February 2014, Mayo Clinic Annual program “ Targeted Therapy for Lung Cancer: A
Case Based Presentation” 9. Miami, FL, January 2014, 10th Annual Miami Cancer Meeting, “Blockades and Barricades in the HER
Family of Receptors” 10. Miami, FL, January 2013, 10th Annual Miami Cancer Meeting, “Blockades and Barricades in the HER
Family of Receptors” 11. San Antonio, TX, December 2012, San Antonio Breast Cancer Conference Symposium 12. Memphis, TN, October 2012, “Consideration in Curative Systemic Therapy of Early Breast Cancer”,
“Evolution of HER2 Directed Therapy in Breast Cancer”. 13. Phoenix, AZ, March 2012, “Options in the Treatment of Metastatic Breast Cancer” 14. Jamaica, NY, February 2012, “Updates in the Treatment of Metastatic Breast Cancer” 15. San Francisco, CA, January 2012 “Breast Cancer Academic Advisory Board” 16. Dallas, TX, December 2011 “Updates from San Antonio Breast Cancer Symposium” 17. New York, NY, August 2011 “17th Annual Perspectives in Breast Cancer” 18. Chicago, IL, May 2011 “American Society Clinical Oncology Conference” 19. Hollywood, FL, April 2011 “12th Annual Palm Beach Cancer Symposium” 20. Hollywood, FL March 2011, “NCCN Global Initiatives”, NCCN Annual Meeting, Industry Roundtable 21. Dallas, TX, April 2011 “NCCN Global Initiatives” at ASBD 22. Tampa, FL, November 2011, “FLASCO Fall Meeting ”
Jahanzeb
06/15
23
23. San Antonio, TX, December 2010 “San Antonio Breast Cancer Conference” 24. Chicago, IL, October 2010 “Treatment of Breast Cancer in the Elderly Women” 25. Key Biscayne, FL, October 2010, “APPNA CME Fall Meeting” 26. Grapevine, TX, July 2010, “APPNA 33rd Annual Seminar Meeting 27. Dallas, TX, July 2010, “Evolution of Therapy in Breast Cancer” 28. Chicago, IL, May 2010 “American Society of Clinical Oncology 29. Hollywood, FL, March 2010, “Bone Complications in Cancer” at the annual NCCN conference for fellows 30. Miami, FL, November 2009, “NSCLC Roundtable at Miami Cancer Conference” 31. Tupelo, MS, October 2009, “Current Updates in the Management of Breast Cancer” 32. San Francisco, CA, October 2009, “Oncology Consultants Live: Practical Considerations in the
Treatment of Breast Cancer” 33. New York, NY August 2009, 15th Annual Perspectives in Breast Cancer, “What therapy should be given
pre-operatively for HER2 positive breast cancer?” 34. New York, NY, August 2009, 15th Annual Perspectives in Breast Cancer, “HER2 – positive metastatic
disease and overcoming resistance to anti-HER2 therapy” 35. Hilton Head, SC, July 2009, “Role of VEGF and VEGFR Targeted Therapy on Breast Cancer” 36. San Francisco, CA, July 2009, NCCN Academy for Excellence and Leadership in Oncology, “Working
Effectively with Key Decision Makers in the U.S. Cancer Care Delivery System”
37. Philadelphia, PA, March 2009, “Current Updates in the Treatment of Breast Cancer – 2009”
38. Tampa, FL, February 2009, “Optimizing treatment options for Non-Small Cell Lung Cancer in the Era of Targeted Therapies”
39. Chicago, IL, October 2008, 10th Annual Lynn Sage Breast Cancer Symposium “Improving
Outcomes of Patients with Adjuvant Endocrine Therapy”
40. Chicago, IL, October 2008, “Breast Cancer Management: Updates, Advances and New Options”
41. Miami, FL, October 2008, “6th Annual Miami Cancer Meeting – Round Table Discussion Moderator”
42. Brooklyn, NY, September 2008, 14th Annual Perspectives in Breast Cancer “Current guidelines and new strategies for treating early HER2-Positive patients”, “Screening for the high risk patient and “Overcoming resistance to Trastuzumab”
43. Brooklyn, NY, September 2008, “NCCN Innovative Diagnostics and Therapeutics in Cancer Care”
44. Boston, MA, August 2008, “ Sanofi-Aventis Oncology lecture Series Speaker Training Workshop”
Jahanzeb
06/15
24
45. New York, NY, March 2008, “Challenging Cases in Breast Cancer–Metastatic Breast CanceER(+)
46. Hollywood, FL, Mar., 2008, “Sunday Brunch: Controversies in the Use of Imaging in the Management of Patients with Cancer”.
47. San Juan, PR, Feb., 2008, “Novel Preoperative Therapy Strategies”
48. Miami, FL, Nov., 2007, “5th Annual Miami Gastrointestinal and Thoracic Oncology Meeting”, Moderator and Panelist.
49. Philadelphia, PA, Sept., 2007, “Adjuvant Traztuzumab in the Older Adult”, NCCN Breast Cancer in The
Older Woman Task Force.
50. Kohala Coast, HI, July, 2007, “The Evolving Utility of Antimetabolites in Breast Cancer”, Future of Breast Cancer Congress.
51. Memphis, TN, May, 2007, “Shifting Paradigms in Curative Management of Breast Cancer”, 24th Annual
53. Hollywood, FL, March, 2007, “Advances in the Treatment of Non-Small Cell Lung Cancer”, NCCN 12th
Annual Conference: Clinical Practice Guidelines & Quality Cancer Care
54. Hollywood, FL, March, 2007, “Management of Colon and Non-Small Cell Lung Cancer: Integrating Second-Line Therapies and Beyond”, NCCN 12th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care.
55. Philadelphia, PA, February, 2007, “Integrating Novel Therapeutic Approaches into the Treatment of
Breast Cancer”, Educational Concepts Group. 56. Denver, CO, February, 2007, “Novel Pre-operative Therapy Strategies”, Current Trends in Breast Cancer
Updates from 2006 SABCS. 57. Boston, MA, February, 2007, “Novel Pre-operative Therapy Strategies”, Current Trends in Breast Cancer,
Updates from 2006 SABCS 58. Washington, DC, January, 2007, “Novel Preoperative Therapy Strategies”, SABCS 2006 Review 59. Hollywood, CA, January, 2007, “Novel Preoperative Therapy Strategies”, Update from SABCS 2006 60. New York, NY, November, 2006, “Biological Agents in Adjuvant Breast Cancer: State of the Art Therapy and Current Challenges”, Annual Chemotherapy Foundation Meeting 61. Las Vegas, NV, October, 2006, “Great Debates in Breast Cancer: Are Taxanes Appropriate for ER+ Patients in the Adjuvant Setting?” 62. Las Vegas, NV, October, 2006, “Supportive Therapy for GI Complications of Chemotherapy” 63. Kohala Coast, HI, August, 2006, “Novel HER2 Targeted Antibody Combinations”, 5th Annual
International Congress on the Future of Breast Cancer.
Jahanzeb
06/15
25
64. Memphis, TN, July, 2006, “Novel Strategies for Treatment of Lung Cancer”
65. Chicago, IL, July, 2006, “Advances in Antibody Therapy of Breast Cancer”, Annual APPNA Symposium
Stage III Non-Small Cell Lung Cancer”, NCCN Clinical Guidelines in Oncology Symposium 67. Oakbrook, IL, April, 2006, “Metastatic Breast Cancer: What is New?” 68. Memphis, TN, March, 2006, “Integrating Novel Therapeutic Approaches into the Treatment of Breast
Cancer” 69. Memphis, TN, January, 2006, “Novel Strategies for the Treatment of Early-Stage Breast Cancer 70. New York, Memorial Sloan Kettering Cancer Center, NCCN Update in Non-Small Cell Lung Cancer,
“Work-up, Prognosis and Markers in NSCLC” 71. Lake Tahoe, NV, October, 2005, “Great Debates in Breast Cancer: The Role of Targeted Adjuvant
Therapy in breast Cancer” 72. Durham, NC, Duke University, October, 2005, NCCN Update in Non-Small Cell Lung Cancer, “Work-up,
Prognosis and Markers in Non-Small Cell Lung Cancer”.
73. Honolulu, HI, August, 2005, “Does Dose Dense Make Sense?
74. San Jose, CA, August, 2005, “Does Dose Dense Make Sense?” 75. Sacramento, CA, August, 2005, Tumor Board 76. Redwood City, CA, August, 2005, “Does Dose Dense Make Sense?” 77. St. Louis, MO, August, 2005, “The Evolving Role of HER2 – Targeted Therapies in Breast Cancer”
78. Baltimore, MD, April, 2005, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, “Workup, Prognostic Factors, and Markers”
79. Columbia, SC, April, 2005, “Clinical Applications: Highlights from the 2004 San Antonio Breast Cancer
Symposium”
80. Hollywood, FL, March, 2005, NCCN Annual Meeting, “Management of Deep Vein Thrombosis in Cancer Patients”
81. Dallas, TX, March, 2005, “Clinical Applications: Highlights from the 2004 San Antonio Breast Cancer
Symposium”
82. Honolulu, HI, August, 2004, NCCN Clinical Practice Guidelines in Oncology Breast Cancer Regional Symposium, “Treatment for Advanced Breast Cancer: Chemotherapy, Immunotherapy, Hormonal Therapy, Bisphosphonates”.
Jahanzeb
06/15
26
83. San Diego, CA, VA Medical Center, May, 2004, “New Advances in the Treatment of 1st Line NSCLC”.
84. Detroit, MI, September, 2003, “Advances in the Treatment of Metastatic Breast Cancer”
85. Milwaukee, WI, July, 2003, “Advances in the Treatment of Metastatic Breast Cancer”
86. Little Rock, AR, May, 2003, “Metastatic Lung Cancer”, University of Arkansas Medical School
87. Las Vegas, NV, February, 2003, Challenging Cases in Oncology Annual CME Meeting, NOCR
88. New York, NY, October, 2002, “Neoadjuvant Therapy in Breast Cancer,” ION meeting
Other Talks as Invited Speaker within the US: 1. Miami, FL, October 2011, “Expert Forum on HER2+ Breast Cancer”
2. Hollywood, FL March 2011, “NCCN Global Initiatives”, NCCN Annual Meeting, Industry Roundtable
3. Port St. Lucie, FL April 2011, “Systemic Treatment of HER2+ Breast Cancer”
4. New York, NY September 2010, “When is enough enough? Panel discussion regarding multiple Chemotherapies, cost/benefit ratio”
5. San Diego, CA May 2010, “Challenging Cases in Breast Cancer”
6. Hollywood, FL March 2010, “A Case-Based Discussion on the Treatment Options for HER2
Positive Metastatic Breast Cancer”
7. McLean, VA November 2009, “The Role of Taxotere (docetaxel) Injection Concentrate in Breast Cancer”
8. Baltimore, MD November 2009, “Molecular Basis of Cancer – Breast” 9. Baltimore, MD November 2009, “Avastin/Herceptin Breast – slides with 1 case study”
10. Baltimore, MD November 2009, “Avastin/Herceptin Breast – slides with 1 case study”
11. Fort Worth, TX November 2009, “The Role of Taxotere (docetaxel) Injection Concentrate in Breast
Cancer”
12. Arlington, TX November 2009, “The Role of Taxotere (docetaxel) Injection Concentrate in Breast Cancer”
13. Grapevine, TX November 2009, “The Role of Taxotere (docetaxel) Injection Concentrate in Breast Cancer”
14. Chicago, IL October 2009, “ Use of Avastin in Breast Cancer”
15. Chicago, IL October 2009, “Avastin Breast/Herceptin Breast Journal Club and Case Studies”
Jahanzeb
06/15
27
16. Chicago, IL October 2009, “ Avastin/Herceptin Breast – slides with 1 case study”
17. Memphis, TN October 2009, “Clinical Correlation: CA and Signal Transduction Inhibitors
Molecular Basis of Disease” to first year medical students at UT Cancer 18. Ventura, CA October 2009, “The Role of Taxotere (docetaxel) Injection Concentrate in Breast
Cancer” 19. Santa Barbara, CA October 2009, “Optimizing treatment options for Non-Small Cell Lung Cancer
in the era of targeted therapies” 20. Costa Mesa, CA September 2009, “Molecular Basis of Cancer – Breast”
21. Los Angeles, CA September 2009, “The Role of Taxotere (docetaxel) Injection Concentrate in
Breast Cancer
22. New York, NY August 2009, “Avastin / Herceptin Breast”
23. Boca Raton, FL August 2009, “Avastin / Herceptin Breast”
24. Atlanta, GA, July 2009, “Avastin Breast / Herceptin Breast”
25. Chicago, IL, June 2009, P4 Healthcare Summit
26. Roseville, CA, June 2009, “Optimizing the Treatment for Non-Small Cell Lung Cancer”
27. Sacramento, CA, June 2009, “Optimizing the Treatment for Non-Small Cell Lung Cancer”
28. Pleasant Hill, CA, June 2009, “Optimizing the Treatment for Non-Small Cell Lung Cancer”
29. Sioux Falls, SD, May 2009, “The Role of Taxotere (docetaxel) Injection Concentrate in Breast Cancer”
30. Grand Forks, ND, May 2009, “The Role of Taxotere (docetaxel) Injection Concentrate in Breast Cancer”
31. Fargo, ND, May 2009, “The Role of Taxotere (docetaxel) Injection Concentrate in Breast Cancer”
32. Memphis, TN, April 2009, “Avastin/Herceptin Breast”
33. New Port Richey, FL, February 2009, “Optimizing treatment options for Non-Small Cell Lung Cancer in the ERA of Targeted Therapies”
34. Bradenton, FL, February 2009, “Optimizing treatment options for Non-Small Cell Lung Cancer in the ERA
of Targeted Therapies”
35. Atlanta, GA, February 2009, “ ERBITUX (Cetuximab) in Non-Small Cell Lung Cancer”
36. San Diego, CA, December 2008 “ the role of Taxotere (Docetaxel) Injection Concentrate in Breast Cancer”
37. New York, NY, November 2008 “ Advanced Non-Small Cell Lung Cancer (NSCLC): Overview of Avastin
and Tarceva”
Jahanzeb
06/15
28
38. Tarrytown, NY, November 2008 “ Advanced Non-Small Cell Lung Cancer (NSCLC): Overview of Avastin
and Tarceva”
39. Norwalk, CT, November 2008 “ The role of Tarceva Tablets in the treatment of Advanced Solid Tumors”
40. Tampa, FL, October 2008, “Taxotere – Early Stage Breast Cancer”
41. Las Vegas, NV, July, 2008, “Challenging Cases in Breast Cancer”.
42. San Francisco, CA, July 2008, “Genomic Health Meeting – Speaker Training”
43. Thorton, Colorado, June 2008, “The Role of Taxotere (docetaxel): Injection Concentrate in Early Stage Breast Cancer”.
44. Colorado Springs, Colorado, June 2008, “The Role of Taxotere (docetaxel): Injection Concentrate in
Early Stage Breast Cancer.
45. Palm Beach Gardens, FL, Apr., 2008, “Targeting HER-2 Positive Breast Cancer: Expanded Options for Herceptin (Trastuzumab) Terapy
46. San Diego, CA, Jan., 2008, “The Role of Taxotere (docetaxel) Injection Concentrate in Early Stage Breast Cancer”
47. Encinitas, CA, Jan., 2008, “The Role of Taxotere (docetaxel) Injection Concentrate in Early Stage Breast Cancer”
48. Port Charlotte, FL, Dec., 2007, “The Role of Taxotere (docetaxel) Injection Concentrate in Early Stage Breast Cancer”
49. West Cape Coral, FL, Dec., 2007, “The Role of Taxotere (docetaxel) Injection Concentrate in Early Stage Breast Cancer”
50. St. Petersbury, FL, Dec., 2007, “Optimizing Treatment Options for NSCLC in the Era of Targeted
Therapies: The Role of Taxotere (docetaxel) Injection Concentrate”
51. Fort Myers, FL, Dec., 2007, “The Role of Taxotere (docetaxel) Injection Concentrate in Early Stage Breast Cancer”
52. Appleton, WI, Oct., 2007, “ An Update in the Treatment of HER2-positive Metastatic Breast Cancer”
53. Green Bay, WI, Oct., 2007, “An Update in the Treatment of HER2-positive Metastatic Breast Cancer”
54. Long Beach, CA, Oct., 2007, “Advances in the Treatment of Early Stage Breast Cancer”
55. Orlando, FL, Sept., 2007, “The Role of Taxotere (docetaxel) Injection Concentrate in Early Stage Breast Cancer”
56. Cocoa, FL, Sept., 2007, “The Role of Taxotere (docetaxel) Injection Concentrate in Early Stage Breast
Cancer”
57. Stuart, FL, Sept., 2007, “The Role of Taxotere (docetaxel) Injection Concentrate in Early Stage Breast
Jahanzeb
06/15
29
Cancer”
58. Boca Raton, FL, Sept., 2007, “The Role of Taxotere (docetaxel) Injection Concentrate in Early Stage Breast Cancer”
59. Jackson, TN, Sept., 2007, “Advances in the Treatment of Early Stage Breast Cancer”
60. La Jolla, CA, August, 2007, “Advances in the Treatment of Early Stage Breast Cancer”
61. San Diego, CA, August, 2007, “Advances in the Treatment of Early Stage Breast Cancer”
62. Chattanooga, TN, July, 2007, An Update in the Treatment of Her2-Positive Metastatic Breast.
63. Chicago, IL, July, 2007, “The Role of Taxotere (docetaxel) Injection Concentrate in Early Stage Breast Cancer”
64. New York, NY, July, 2007, “Bevacizumab in Metastatic Breast Cancer: Clinical Data Discussion”
65. New York, NY, July, 2007, “Role of Bevacizumab in Metastatic Breast Cancer: Discussion”
66. New York, NY, July, 2007, “Practice Patterns in Metastatic Breast Cancer”
67. New York, NY, July, 2007, “Anti-VEGF activity in Breast Cancer Discussion”
68. Boca Raton, FL, July, 2007, “Herceptin (Trastuzumab) for the Adjuvant Treatment of HER2 Positive Node-Positive Breast Cancer”
69. Lansdowne, VA, June, 2007, “Locally advanced breast cancer: BINV-13, BINV-14 Inflammatory breast cancer guideline – separate guideline?”
70. New Port Richey, FL, May, 2007, “Advances in the Treatment of Early Stage Breast Cancer”
71. Bay Pines, FL, May, 2007, “Combination Therapy with Taxotere (docetaxel) Injection Concentrate for Chemotherapy-Naive Advanced Non-Small Cell Lung Cancer Patients”
72. Ocala, FL, May, 2007, “Advances in the Treatment of Early Stage Breast Cancer”
73. White Plains, CT, March 2007, “The Role of Tarceva (erlotinib) Tablets in the Treatment of Solid Tumors: An Advance in Second-Line Treatment of Advanced Non-Small Cell Lunch Cancer”
74. Greenwich, CT, March, 2007, “The Role of Tarceva (erlotinib) Tablets in the Treatment of Solid Tumors: An Advance in Second-Line Treatment of Advanced Non-Small Cell Lunch Cancer”
75. Hollywood, FL, March, 2007, “Advances in the Treatment of Non-Small Cell Lung Cancer”
76. Roseville, CA, February, 2007, “Advances in the Treatment of Early Stage Breast Cancer”
77. Modesto, CA, February, 2007, “Advances in the Treatment of Early Stage Breast Cancer”
78. Sacramento, CA, February, 2007, “Advances in the Treatment of Early Stage Breast Cancer”
79. Folson, CA, February, 2007, “Advances in the Treatment of Early Stage Breast Cancer”
Jahanzeb
06/15
30
80. Oakland, CA, February, 2007, “Advances in the Treatment of Early Stage Breast Cancer”
81. Fremont, CA, February, 2007, “Advances in the Treatment of Early Stage Breast Cancer”
82. Canton, OH, February, 2007, “Avastin and Tarceva in Non-Small Cell Lung Cancer”
83. Akron, OH, February, 2007, Aultman Cancer Center, “Update on Chemotherapy and Targeted Therapies: San Antonio Breast Cancer Symposium Update”
84. Chicago, IL, January, 2007, “New Innovation in Cancer: Current and Immenant Application”
85. Coral Springs, FL, January, 2007, “Taxotere (docetaxel) for Injection Concentrate in Metastatic Breast Cancer”
86. Orange, CA, January, 2007, “Avastin and Tarceva in the Treatment of Lung Cancer”
87. Riverside, CA, January, 2007, “Chemotherapy with Taxotere (docetaxel) Injection Concentrate for Chemotherapy –Naive Advanced NSCLC Patients”
88. Duarte, CA, January, 2007, “Avastin and Tarceva in the Treatment of Non Small Cell Lung Cancer”
89. Mission Hills, CA, January, 2007, “Avastin and Tarceva in the Treatment of Non Small Cell Lung Cancer”
90. Bradenton, FL, January, 2007, “Advances in the Treatment of Early Stage Breast Cancer”
91. Dunedin, FL, January, 2007, “Advances in the Treatment of Early Stage Breast Cancer”
92. Kissimmee, FL, January, 2007, “Tarceva Tablets: An Advance in the Second-Line Treatment of Non Small Cell Lung Cancer”
93. Kissimmee, FL, January, 2007, “Targeting VEGF in Non-Small Cell Lung Cancer: An Overview of
Avastin”
94. Brooksville, FL, January, 2007, “Advances in the Treatment of Easly Stage Breast Cancer”
95. Inverness, FL, January, 2007, “Advances in the Treatment of Easly Stage Breast Cancer”
96. New York, NY, December, 2006, “Phase II/III Trials of Bevacizumab in MBC: Discussion”
97. Chicago, IL, October, 2006, “New Innovations in Cancer Care: Current and Imminent Applications”, NCCN Case Management Study
98. Miami, FL, October, 2006, “Challenging Cases in Breast Cancer: Metastatic Breast Cancer
Hepatic Mets After Adjuvant Therapy”
99. Folsom, CA, September, 2006 “Combination Therapy for Chemotherapy – Naive Advanced NSCLC Patients”
100. Roseville, CA, September, 2006 “Combination Therapy for Chemotherapy – Naive Advanced NSCLC Patients”
Jahanzeb
06/15
31
101. Sacramento, CA, September, 2006 “Combination Therapy for Chemotherapy – Naive Advance NSCLC Patients”
102. Stockton, CA, September, 2006 “Combination Therapy for Chemotherapy – Naive Advanced NSCLC Patients”
103. Lake Worth, FL, September, 2006, “HER2 Targeted Therapy in the Treatment of Metastatic Breast Cancer
104. Miami, FL, September, 2006, Taxotere (docetaxel) for Injection Concentrate in Metastatic Breast Cancer”
105. Lake Worth, FL, August, 2006, “HER2 Targeted Therapy in the Treatment of Metastatic Breast Cancer”
106. Orlando, FL, August, 2006, “HER2 Targeted Therapy in the Treatment of Metastatic Breast Cancer.
107. Los Angeles, CA, August, 2006, “Combination Therapy with Taxotere (docetaxel) Injection Concentrate for Chemotherapy – Naive Advanced NSCLC Patients”
108. San Diego, CA, May, 2006, “Challenging Cases in Geriatric Oncology: Adjuvant Breast Cancer &
Supportive Care Therapy”
109. San Diego, CA, May, 2006, “Challenging Cases in Geriatric Oncology: Metastatic Breast Cancer following Adjuvant Therapy”
110. Wilmington, DE, May, 2006, “Advances in the Treatment of Early Stage Breast Cancer”
111. Chevy Chase, MD, May, 2006, “Advances in the Treatment of Early Stage Breast Cancer”
112. Baltimore, MD, May, 2006, “Advances in the Treatment of Early Stage Breast Cancer”
113. Pikesville, MD, May, 2006, “Advances in the Treatment of Early Stage Breast Cancer”
114. Sacramento, CA, February, 2006, “Advances in the Treatment of Early Stage Breast Cancer”
115. Fairfield, CA, February, 2006, “Advances in the Treatment of Early Stage Breast Cancer”
116. Roseville, Ca, February, 2006, “Advances in the Treatment of Early Stage Breast Cancer”
117. Sacramento, CA, February, 2006, “Advance in the Treatment of Early Stage Breast Cancer”
118. Memphis, TN, January, 2006, “Novel Strategies for the Treatment of Early-Stage Breast Cancer (including adjuvant hormonal therapy trials, ongoing endocrine prevention trials, HER2-directed antibodies in adjuvant therapy, taxane combinations, and genomic tools for prediction of recurrence risks)
119. La Jolla, CA, January, 2006, “Advances in the Treatment of Early Stage Breast Cancer”
120. Dallas, TX, November, 2005, “Taxotere in Breast Cancer Management”
121. Miami, FL, November, 2005, “Abraxane Development Program”
123. Miami, FL, November, 2005, “Review of Comparative Experience with Taxanes in Treatment of
Jahanzeb
06/15
32
Metastatic Breast Cancer”
124. Oklahoma City, OK, October, 2005, “Advances for the 1st Line Treatment of Patients with HER2+ Metastatic Breast Cancer: The Role of Herceptin (Trastuzumab)”
127. Las Vegas, NV, September, 2005, “Case Study of Neoadjuvant Hormonal Therapy – ER(+)”
128. Las Vegas, NV, September, 2005, “Case Study of Neoadjuvant Chemotherapy – HER2(+)”
129. St. Louis, MO, August, 2005, “The Role of Tarceva (erlotinib) in the Treatment of Locally Advanced or Metastatic NSCLC After Chemotherapy Failure”
130. Kansas City, MO, August, 2005, “The Role of Tarceva (erlotinib) in the Treatment of Locally
Advanced or Metastatic NSCLC After Chemotherapy Failure”
131. Kansas City, MO, August, 2005 “The Role of Tarceva (erlotinib) in the Treatment of Locally Advanced or Metastatic NSCLC After Chemotherapy Failure”
132. St. Louis, MO, August, 2005 “The Evolving Role of HER2 – Targeted Therapies in Breast Cancer”
133. Miami, FL, June, 2005, “Role of Adjuvant Chemotherapy for Non-Small Cell Lung Cancer”
134. Memphis, TN, June, 2005, St. Jude Children’s Research Hospital, “Cancer and Cancer Care”
135. Scottsdale, AZ, June, 2005, “Metastatic Breast Cancer – Novel Taxanes, A Case Study.”
136. Scottsdale, AZ, June, 2005, “Neoadjuvant Hormonal Therapy – ER(+), A Case Study.”
137. Huntington Beach, CA, April, 2005, “Early Stage Breast Cancer Clinical Overview”
138. Philadelphia, PA, April, 2005, “The Role of Taxanes in the Metastatic Setting for Breast Cancer”
139. Philadelphia, PA, April, 2005, “ Use of Taxanes in the Neoadjuvant and Adjuvant Settings”
140. Baltimore, MD, April, 2005, “The Evolving Role of HER2-Targeted Therapies in Breast Cancer”
141. Stuart, FL, March, 2005, “New Advances in the Treatment of NSCLC”
142. Lake Worth, FL, March, 2005, “New Advances in the Treatment of NSCLC”
143. Dallas, TX, March, 2005, “Recent Developments in Chemotherapy of NSCLC”
144. Dallas, TX, March, 2005, “New Advances in the Treatment of 1st Line NSCLC”
145. Christiansburg, VA, February, 2005, “New Advances in the Treatment of 1st Line NSCLC”
146. Danville, VA, February, 2005, “New Advances in the Treatment of 1st Line NSCLC”
Jahanzeb
06/15
33
147. Bluefield, VA, February, 2005, “New Advances in the Treatment of 1st Line NSCLC”
148. Boca Raton, FL, January, 2005, “ Recent Developments in Chemotherapy of NSCLC”
149. Boca Raton, FL, January, 2005, “New Advances in the Treatment of 1st Line NSCLC”
150. Ft. Lauderdale, FL, November, 2004, “Breast Cancer: Choice of Therapy: A Case Study”
151. Ft. Lauderdale, FL, November, 2004, “Role of Taxanes and Their Progeny in Advanced Breast Cancer: A Case Study”
152. Coral Springs, FL, November, 2004, “New Advances in the Treatment of 1st Line NSCLC”
153. New Orleans, LA, October, 2004, “Adjuvant Therapy in Breast Cancer: A Case Study”
154. New Orleans, LA, October, 2004, “The Role of Taxanes in Metastatic Breast Cancer: A Case Study”
155. Center Valley, PA, October, 2004, “New Advances in the Treatment of lst Line NSCLC”
156. Darby, PA, October, 2004, “New Advances in the treatment of 1st Line NSCLC”
157. Philadelphia, PA, October, 2004, “New Advances in the Treatment of lst Line NSCLC”
158. Cherry Hill, NJ, October, 2004, “Advances in the Treatment of Metastatic Breast Cancer”
159. Huntingdon Valley, PA, October, 2004, “New Advances in the Treatment of 1st Line NSCLC”
160. Irving, TX, September, 2004, “A Review of Taxotere (docetaxel) in the Treatment of Early Stage Breast Cancer: Adjuvant Clinical Overview”
161. Wauwatosa, WI, September, 2004, “Early Stage Breast Cancer”
162. Mequon, WI, September, 2004, “Lung and Breast Cancer”
163. Wauwatosa, WI, September, 2004, “New Advances in the Treatment of Lung Cancer”
164. Sheboygan, WI, September, 2004, “Lung and Breast Cancer”
165. Park City, UT, August, 2004, NCCN Breast Cancer Panel, “Neoadjuvant Endocrine Therapy in Hormonal Receptive Breast Cancer”.
166. Seattle, WA, August, 2004, “Advances in the Treatment of Metastatic Breast Cancer”
167. Renton, WA, August, 2004, “Advances in the Treatment of Metastatic Breast Cancer”
168. Edmonds, WA, August, 2004,”Advances in the Treatment of Metastatic Breast Cancer”
169. Maui, HI, August, 2004, “New Advances in the Treatment of 1st Line NSCLC”.
170. Honolulu, HI, August, 2004, “New Advances in the Treatment of 1st Line NSCLC”.
Jahanzeb
06/15
34
171. Dallas, TX, Texas Oncology, June, 2004, “Advances in the Treatment of Metastatic Breast Cancer”.
172. Dallas, TX, Center for Oncology Research and Treatment, June, 2004, “Advances in the Treatment of Metastatic Breast Cancer”.
173. Dallas, TX, June, 2004, “Advances in the Treatment of Metastatic Breast Cancer”.
174. Austin, TX, June, 2004, “Advances in the Treatment of Metastatic Breast Cancer”.
175. Irving, TX, June, 2004, “Advances in the Treatment of Metastatic Breast Cancer”.
176. Placentia, CA, May, 2004, “New Advances in the Treatment of 1st Line NSCLC”.
177. Orange, CA, May, 2004, “New Advances in the Treatment of 1st Line NSCLC”.
178. Newport Beach, CA, May, 2004, “New Advances in the Treatment of 1st Line NSCLC”.
179. Riverside, CA, May, 2004, “New Advances in the Treatment of 1st Line NSCLC”.
180. San Diego, CA, VA Medical Center, May, 2004, “New Advances in the Treatment of 1st Line NSCLC”.
181. Soquel, CA, May, 2004, “Advances in the Treatment of Metastatic Breast Cancer”.
182. Oakland, CA, May, 2004, “Advances in the Treatment of Metastatic Breast Cancer”.
183. Monterey, CA, May, 2004, “Advances in the Treatment of Metastatic Breast Cancer”.
184. Scottsdale, AZ, April, 2004, “What is the Current Standard for Adjuvant Therapy in Breast Cancer”?
185. Phoenix, AZ, April, 2004, “New Advances in the Treatment of 1st Line NSCLC”
186. Paradise Valley, AZ, April, 2004, “New Advances in the Treatment of 1st Line NSCLC”
307. Keystone, CO, June, 2001, “New Advances in the Treatment of 2nd Line Non-Small Cell Lung Cancer”
308. Denver, CO, June, 2001, “New Advances in the Treatment of 2nd Line Non-Small Cell Lung Cancer"
309. New Orleans, LA, June, 2001, “Taxotere in Hormone Refractory Prostate Cancer,” Advisory Board Meeting
310. Philadelphia, PA, June, 2001, Oncology Speakers Bureau
311. St. Michael’s, MD, June, 2001, “Metastatic Breast Cancer: A Focus on Taxotere,” Advisory Board Meeting
312. St. Michael’s, MD, June, 2001, “Taxotere in Adjuvant Breast Cancer,” Advisory Board Meeting
Jahanzeb
06/15
40
313. Bryn Mawr, PA, June, 2001, “Update in the Treatment of Non-Small Cell Lung Cancer”
314. Denver, CO, June, 2001, “New Advances in the Treatment of 2nd Line Non-Small Cell Lung Cancer"
315. New York, NY, April, 2001, “Lung Cancer Overview,” “Disease Progression and Clinical Decision Making”, “Taxotere 2nd Line,” Oncology Initial Sales Training Class
316. Orlando, FL, March, 2001, “New Advances in the Treatment of 2nd Line Non-Small Cell Lung Cancer”
317. New York, NY, April, 2001 “Taxotere Combinations in Breast Cancer”
318. Laguna Beach, CA, March, 2001, “Taxotere Options in Breast Cancer”
319. Modesto, CA, March, 2001, “Taxotere Options for 2nd Line Non-Small Cell Lung Cancer Patients”
320. Palo Alto, CA, March, 2001, “New Advances in the Treatment of 2nd Line Non-Small Cell Lung Cancer”
321. Soquel, CA, March, 2001, “Taxotere New Option for 2nd Line Non-Small Cell Lung Cancer Patients”
322. Fontana, CA, February, 2001, “Advances in the Treatment of Metastatic Breast Cancer,” Kaiser Permanente Medical Center
323. Los Angeles, CA, February, 2001, “New Advances in the Treatment of 2nd Line Non-Small Cell Lung
Cancer"
324. New York, NY, February, 2001, “Lung Cancer Overview,” “Disease Progression and Clinical Decision Making,” “Taxotere 2nd Line,” Oncology Initial Sales Training Class
325. Los Angeles, CA, February, 2001, “Advances in the Treatment of Metastatic Breast Cancer,” Kaiser
Permanente Medical Center 326. Laguna Hills, CA, February, 2001, “Recent Advances in the Treatment of Both Metastatic Breast
Cancer and Non-Small Cell Lung Cancer," Saddleback Memorial Medical Center 327. Pasadena, CA, February, 2001, “Advances in the Treatment of Metastatic Breast Cancer” 328. Burbank, CA, February, 2001, “Advances in the Treatment of Non-Small Cell Lung Cancer,”
Providence St. Joseph Medical Center 329. Lakeland, FL, February, 2001, “New Advances in Non-Small Cell Lung Cancer,” Lakeland
Regional Medical Center 330. Keystone, CO, February, 2001, “Taxotere in NSCLC,” Taxotere Advisory Board 331. New Rochelle, NY, January, 2001, “New Advances in the Treatment of 2nd Line Non-Small Cell Lung
Cancer,” Sound Shore Cancer Center 332. White Plains, NY, January, 2001, “New Advances in the Treatment of 2nd Line Non-Small Cell Lung
Cancer,” Dickstein Cancer Center
333. Bronxville, NY, January, 2001, “New Advances in the Treatment of 2nd Line Non-Small Cell Lung Cancer,” Montefiore Medical Center
Jahanzeb
06/15
41
334. Garden City, NY, January 18, 2001, “New Advances in the Treatment of 2nd Line Non-Small Cell Lung
Cancer” 335. New York, NY, January, 17, 2001, “ New Advances in the Treatment of 2nd Line Non-Small Cell Lung
Cancer” 336. Las Vegas, NV, December, 2000, “Taxane Therapy in the Treatment of Solid Tumors,” American
Society of Health System Pharmacists 337. Atlanta, GA, December, 2000, “New Advances in the Treatment of 2nd Line Non-Small Cell Lung
Cancer,” Oncology Speakers Bureau
338. Little Rock, AK, December, 2000, “Overview of Taxotere in Metastatic Breast Cancer”
339. Birmingham, AL, November, 2000, “Taxotere in Metastatic Breast Cancer”
340. Pomona, CA, November, 2000, “New Advances in the Treatment of 2nd Line Non-Small Cell Lung Cancer,” Pomona Medical Center
341. Ontario, CA, November, 2000, “New Advances in the Treatment of 2nd Line Non-Small Cell Lung
Cancer”
342. Victorville, CA, November, 2000, “Advances in the Treatment of Non-Small Cell Lung Cancer," Victor Valley Community Hospital
343. Colton, CA, October, 2000, “New Advances in the Treatment of 2nd Line Non-Small Cell Lung Cancer,” Arrowhead Regional Medical Center
344. Maui, HI, October, 2000, “Taxotere in the Treatment of Breast Cancer”
345. Maui, HI, October, 2000, “Taxotere in the Treatment of Non-Small Cell Lung Cancer”
346. Honolulu, HI, October, 2000, “New Advances in Non-Small Cell Lung Cancer,” St. Francis Medical Center
417. Port Richey, FL, November, 1998, “Update on Non-Small Cell Lung Cancer”
418. Fort Lauderdale, FL, November, 1998, “Advances in the Treatment of Lung Cancer”
419. Miami, FL, November, 1998, “Combinations of Chemotherapy in Lung Cancer,” University of Miami Sylvester Comprehensive Cancer Center Symposium “Focus on Tumors: Lung and Thoracic”
420. Tampa, FL, October, 1998, “Advances in the Treatment of Breast Cancer”
421. Chicago, IL, October, 1998, “Advances in the Treatment of Breast Cancer,” Sequus Speakers Education Program
422. Cromwell, CT, October, 1998, “Advances in the Treatment of Breast Cancer”
423. Norwich CT, October, 1998, “Advances in the Treatment of Breast Cancer”
430. Fort Lauderdale, FL, July, 1998, “Multimodality Therapy in Non-Small Cell Lung Carcinoma,”
Cleveland Clinic, Florida 431. Portland, OR, June, 1998, “Fatigue in Lung Cancer Patients,” ALCASE Distinguished Faculty Program 432. St. Louis, MO, June, 1998, Lung Cancer “Locally Advanced Disease – Potential for Curability,” Cancer
Management for Practitioners, Washington University School of Medicine 433. Orlando, FL, June, 1998, “Overview of Taxotere in Locally Advanced or Metastatic Breast Cancer,”
Taxotere Advisory Board Meeting 434. Coeur D’Alene, Idaho, June, 1998, “Overview of Taxotere in Locally Advanced or Metastatic Breast
Cancer”
435. Boston, MA, June, 1998, “Overview of Taxotere in Locally Advanced or Metastatic Breast Cancer,” Taxotere Advisory Board Meeting
Jahanzeb
06/15
46
436. San Francisco, CA, June, 1998, “Lymphoma Diagnosis and Treatment Review,” Genentech
Oncology Training Session
437. Boca Raton, FL, June, 1998, “Advances in the Treatment of Anthracycline Resistant Metastatic Breast Cancer,” RPR Oncology Speakers Bureau
438. Los Angeles, CA, May, 1998, “A Phase I Trial of Gemcitabine and Vinorelbine Employing Planned Half
Doses on Day 8 in Patients With Refractory Solid Tumors,” Poster Presentation, Glaxo Welcome Investigator’s Meeting
439. Fogelsville, PA, April, 1998, “Chemotherapy in Breast Cancer,” Lehigh Valley Oncology Society Meeting
440. Baltimore, MD, February, 1998, “Update: A Review of New Clinical Data on Taxotere in Locally Advanced or Metastatic Breast Cancer,” Taxotere Local Advisory Board Meetings
441. Short Hills, NJ, February, 1998, “Update: A Review of New Clinical Data on Taxotere in Locally
Advanced or Metastatic Breast Cancer,” Taxotere Local Advisory Board Meeting
442. Fort Lauderdale, FL, December, 1997, “Recent Advances in the Treatment of Breast Cancer”
443. Boca Raton, FL November, 1997, “Lung Cancer: How to Answer the Unanswered Questions,” CME Symposium
444. Boca Raton, FL, November, 1997, “Present and Future Role of Chemotherapy in Non-Small Cell
Lung Carcinoma,” CME Symposium
445. Stuart, FL, November, 1997, “Advances in the Treatment of Non-Small Cell Lung Cancer,” Oncology Grand Rounds, Martin Memorial Hospital
446. Little Rock, AK, August, 1997, “Advances in Treatment of Breast Cancer,” Breast Cancer Initiative
Program
447. La Jolla, CA, June, 1997, “Taxotere in Breast Cancer: Have We Discovered The Most Active Drug?" Breast Cancer Initiative Dinner at UCSD Perlman Cancer Center
448. Boston, MA, June, 1997, “Taxotere in Breast Cancer,” Area Advisory Board Meeting
449. Richmond, VA, July, 1997, “Taxotere in Breast Cancer,” Area Advisory Board Meeting
450. Boston, MA, January, 1997, “Taxotere in Anthracycline Resistant Metastatic Breast Cancer”
451. Boca Raton, FL, February, 1997, “Non-Small Lung Cancer: How to Answer the Unanswered Questions”
452. Hartford, CT, January, 1997, “Taxotere in Anthracycline Resistant Metastatic Breast Cancer”
453. San Antonio, TX, December, 1996, “Navelbine in the Elderly Breast Cancer Patients,” Glaxo Welcome seminar on “Navelbine: Emerging Data in Solid Tumors
459. Cedar Rapids, IA, October, 1994, “Navelbine in Non-Small Cell Lung Cancer,” at Fall Meeting of Iowa Oncology Society
460. St. Louis, MO, August, 1994, “Role of chemotherapy in non-small cell lung cancer,” at weekly
conference of Mallinckrodt Institute of Radiology, Division of Radiation Oncology
461. St. Louis, MO, August, 1994, “Role of chemotherapy in non-small cell lung cancer,” Grand Rounds at the VA Hospital
462. St. Louis, MO, August, 1994, “Combined modality therapy in non-small cell lung cancer,” Grand Rounds
at the VA Hospital
463. St. Louis, MO, May, 1992, “Multimodality approach in lung cancer,” Continuing Medical Education Conference at Washington University (an update in thoracic surgery)
Cooperative Group/Experts Round Table/Speakers Bureau Meetings by Invitation: 05/15 APPNA Spring Meeting, Washington D.C. 05/15 ASCO Annual Meeting, Chicago IL 04/15 EPIC Metastatic Breast Cancer, Las Vegas NV 01/15 Quest Diagnostics Breast Cancer Advisory Board, Hollywood, FL 11/14 US Payor / Provider Advisory Board Oncology, Atlanta, FL 11/14 Tampa, FL, November 2014, “FLASCO Fall Meeting” 8/14 APPNA 37th Annual Convention, Washington D.C. 5/14 ASCO Annual Meeting, Chicago, IL 4/14 FLASCO Business Oncology, Spring Session and Meeting, Orlando FL
Jahanzeb
06/15
48
3/14 EPIC Metastic Breast Cancer in 2014 and Beyond: An Expert Round Table, Dallas TX 3/14 APPNA Spring Meeting, Beverly Hills, CA 5/13 ASCO Annual Meeting, Chicago, IL 3/13 Ventana Medical Systems, Breast Cancer Diagnostic Advisory Board Meeting, Baltimore, MD 1/13 Lilly JFCK ISST Meeting, Ft. Lauderdale, FL 12/12 Genentech Breast Cancer National Advisory Board, San Antonio, TX 11/12 FLASCO Business Oncology, Fall Session and Meeting, Tampa, FL 10/12 Abbott Investigator Meeting, Chicago, IL 7/12 NCCN Non-Small Cell Lung Cancer Panel Annual Meeting, 7/12 APPNA 35th Annual Summer Meeting, Washington, DC 5/12 ASCO Annual Meeting, Chicago, IL 5/12 HER2 Registry Steering Committee Meeting, Chicago, IL 5/12 Xcenda “Challenging Cases in Breast and Lung Cancer”, Ft. Lauderdale, FL 5/12 Genentech Breast Cancer National Advisory Board, Durham, NC 4/12 FLASCO Business Oncology, Spring Session and Annual Meeting, Orlando, FL 3/12 Breast Cancer Regional Advisory Board, Miami, FL 12/11 Genentech Breast Cancer National Advisory Board, San Antonio, TX 11/11 Tampa, FL, November 2011, “FLASCO Fall Meeting” 11/11 Roche Global Advisory Board Meeting, Hoboken, NJ 8/11 Roche 1st Symposium Treatment with Care, Mexico City, Mexico 7/11 NCCN/GLICO Global Initiatives, Rio de Janeiro, Brazil 6/11 NCCN Non-Small Cell Lung Cancer Panel Meeting, Philadelphia, PA 4/11 Roche Academic Presentations on Avastin for NSCLC and Breast Cancer, Johannesburg, SA 3/11 NCCN Annual Meeting, Hollywood, FL 12/10 Genentech National Breast Cancer Advisory Board, San Antonio, TX 12/10 Novartis: SABCS Advisory Board, San Antonio, TX
Jahanzeb
06/15
49
12/10 Avastin Ribbon 2 Steering Committee, San Antonio, TX 10/10 Zybrest Lung Advisory Panel, San Francisco, CA 09/10 ARIES Lung Steering Committee, Chicago, IL 07/10 ICORE Advisory Board, New York, NY 07/10 NCCN Academy, Panelist, Philadelphia, PA 05/10 CRIPTO/Light HER2 Breast Cancer Advisory Board, Miami, FL 05/10 NCCN Academy Summit – Round Table Discussion, Washington, DC 10/09 Mid-South Cancer Symposium Moderator – Round Table discussion Panel, Memphis, TN 10/09 ARIES Lung Steering Committee, Chicago, IL 10/09 Miami Cancer Meeting, “Developments in Cancer Care in the 21st Century Lung Cancer Round Table”, Miami, FL 10/09 Xeloda Breast Cancer Advisory Board, San Francisco, CA 09/09 Abraxis Advisory Board, San Francisco, CA 08/09 Avastin Breast Cancer Center Regional Advisory Board, Chicago, IL 04/09 Herceptin Advisory Board, Seattle, WA 04/09 Avastin Sales and Marketing Meeting, Chicago, IL 10/08 Southwest Oncology Group Meeting (SWOG), Chicago, IL 10/08 Cetuximab in NSCLC Clinical Forum, Miami, FL 08/08 Sanofi-Aventis Oncology Lecture Series Speaker Training, Boston, MA 05/08 NCCN Bendamustine Scientific Review Committee Meeting, Washington, DC 05/08 Herceptin, Experts Round Table, Chicago, IL 05/08 Mammaprint / Agenda Expert Round Table, Chicago, IL 05/08 Southwest Oncology Group Meeting (SWOG), Atlanta, GA 03/08 NMCR Challenging Cases in Breast Cancer, New York, NY 02/08 Genentech Oncology Moderator Orientation Meeting, Miami, FL 01/08 ASCO Quality Oncology Practice Initiative Meeting, Alexandria, VA 01/08 Breast Experts Tumor Board, Genentech National Sales Meeting, San Diego, CA
Jahanzeb
06/15
50
11/07 NCCN Bendamustine Scientific Advisory Board, Philadelphia, PA 11/07 Herceptin Nurse Advisory Board Meeting, Newport Beach, CA 10/07 Avastin Community Experts Breast Cancer Advisory Board, San Francisco, CA 10/07 Southwest Oncology Group Meeting, Huntington Beach, CA 09/07 NCCN Breast Cancer in the Older Woman Task Force Meeting, Philadelphia, PA 08/07 NCCN Oncology Research Program (ORP) Strategic Planning Meeting, Chicago, IL 07/07 NCCN Abraxane Scientific Advisory Board Meeting, Washington, DC 06/07 NCCN Breast Panel, Lansdowne, VA 05/07 NCCN Non-Small Cell Lung Cancer Panel, Chicago, IL 05/07 Southwest Oncology Group Meeting, Chicago, IL 10/06 ASCO Item Writing Workshop, Chicago, IL 10/06 Southwest Oncology Group Meeting, Seattle, WA 09/06 Novacea Virtual Webcast of Top Tier Key Opinion Leaders, New York, NY 07/06 Tarceva Speakers Bureau, New York, NY 07/06 New Approaches to Lung Cancer: Translating Clinical Research into Clinical Practice Faculty Training
Program, Chicago, IL 04/06 Southwest Oncology Group Meeting, Salt Lake City, UT 02/06 NCCN HER2 Testing in Breast Cancer Task Force Meeting, Chicago, IL 01/06 Berlex Consultant Meeting, San Diego, CA 12/05 Avastin Regional Academic Breast Cancer Advisory Board Meeting, San Antonio, TX 12/05 Aventis Consultants Meeting, San Antonio, TX 12/05 VERN Metastatic Breast Cancer Curriculum Review Meeting, San Antonio, TX 09/05 Taxotere (docetaxel) KOL Meeting, New York, NY 09/05 Southwest Oncology Group Meeting, New Orleans, LA 07/05 Taxotere (docetaxel) Breast and Lung Cancer Consultant Program, Seattle, WA 07/05 Taxotere (docetaxel) Breast and Lung Cancer Consultant Program, New Orleans, LA
Jahanzeb
06/15
51
07/05 NCCN Breast Cancer Panel Meeting, Chicago, IL 07/05 VEGF Educational Resource Network Focus on Non-Small Cell Lung Cancer, Chicago, IL 06/05 NCCN Non-Small Cell Lung Cancer Panel Meeting, Chicago, IL 07/05 Taxotere (docetaxel) Breast Consultant Program, Atlanta, GA 07/05 NOCR Challenging Cases in Breast Cancer, Scottsdale, AZ 05/05 NCCN Breast Adjuvant Task Force Meeting, Chicago, IL 04/05 Herceptin Advisory Board, Beverly Hills, CA 04/05 Southwest Oncology Group Meeting, Denver, CO 04/05 NCCN Non-Small cell Lung Cancer Guidelines, Baltimore, MD 03/05 Taxotere (docetaxel) Speaker Summit, Bonita Springs, FL 02/05 Tarceva Regional Lung Advisory Board Meeting, New York, NY 02/05 QOPI Planning Meeting, Alexandria, VA 01/05 Genomics in Breast Cancer Oncotype DX Summit, Phoenix, AR 10/04 Southwest Oncology Group Meeting, Kansas City, MO 08/04 NCCN Breast Cancer Panel Meeting, Salt Lake City, UT 07/04 Fragmin Oncology Guidelines Steering Committee, New York, NY 11/04 Genasense Scientific Exchange Meeting, Boston, MA 04/04 Southwest Oncology Group Meeting, Huntington Beach, CA 11/03 Abraxane KOL Advisory Board, New York, NY 10/03 EMD Pharmaceuticals Oncology Advisory Board, Dallas, TX 10/03 Southwest Oncology Group Meeting, Seattle, WA 07/03 NCCN Breast Cancer Panel Meeting, Scottsdale, AZ 04/03 Southwest Oncology Group Meeting, San Diego, CA 01/03 EMD Pharmaceuticals Oncology Advisory Board, Naples, FL 12/02 NCCN Non-Small Cell Lung Cancer Panel, Chicago, IL 10/02 Access to Cancer Care and National Initiatives in Quality Cancer Care, NCCN Cancer Policy Summit,
Washington, DC
Jahanzeb
06/15
52
12/02 The Year 2002 Process: An Evidenced Based Approach for the Treatment of Advanced Non-Small Cell
Lung Cancer, New York, NY 12/01 Process of Care in Metastatic Breast Cancer, San Antonio Breast Cancer Symposium, San Antonio, TX 11/96 Rationale of Studying Doxil in Advanced Breast Cancer, Tucson, AZ National Audio / Web Conferences: 04/14- 04/15 “ImmunoOncology in Melanoma and Lung Cancer” 08/07/09 “Avastin Breast / Herceptin Breast” 09/22/08 “Current Debates in the Treatment of HER 2+ Metastatic Breast Cancer” 08/07 – 12/07 “New Developments in the Management of Advanced Breast Cancer”, 3 programs 08/09/06 “Controversies Surrounding the Optimal Use of Chemotherapy in Breast Cancer” 11/02 – 03//03 “Off-label use of Herceptin within Managed Care Settings and Hospitals” 4 programs 10/02 – 11/02 “Targeted Therapies for Advanced Breast Cancer” 4 programs 07/02 – 09/02 “HER2 Testing in Breast Cancer: What is the Best Strategy” 4 programs 01/02 – 04/02 “Update in Chemotherapy of Metastatic Breast Cancer” 8 programs 06/01 – 09/01 “Advances in the Management of Metastatic Breast Cancer” 11 presentations 04/97 – 07/97 “Role of Doxil in the Treatment of Solid Tumors” 15 presentations, 1,352 participants, 192 sites. Publications: Original Publications: 1. J D. Maltzman, E Felip, N Leighl, M Thomas, P Fatato, K Hoffman, W Wang, O Majid, M Jahanzeb, “A
Randomized, Double-Blind, Placebo-Controlled, Study of the Safety and Efficacy of Farletuzumab in Combination With a Platinum Containing Doublet in Chemotherapy-Naїve Subjects With Stage IV Adenocarcinoma of the Lung” Submitted
2. Wozniak AJ, Kosty MP, Jahanzeb M, Brahmer JR, Spigel D, Leon L, Fish S, Flick ED, Hazard SJ, Lynch Jr
TJ, “Clinical Outcomes in Elderly Patients with Advanmoced Non-Small Cell Lung Cancer: Results from ARIES, a Bevacizumab Observational Cohort Study” Accepted January 2015.
3. MP Kosty, 1 A Wozniak, 2 M Jahanzeb, 3 L Leon, 4 S. Fish, 4 S. Hazard, 4 TJ Lynch Jr5: Effectiveness and safety of post-induction phase bevacizumab treatment for patients with non-small cell lung cancer: results from the ARIES observational cohort study 2014. Targeted Oncology, Accepted January 2015.
Jahanzeb M, Johnston S RD, Korde LA, Khatcheressian JL, Mehta RS, Muss HB, Burstein HJ, Endocrine therapy for hormone receptor positive metastatic breast cancer: American Society of Clinical Oncology Guideline. Journal of Clinical Oncology, accepted October 2014.
5. L Leon,1 M Kosty,2 M Jahanzeb,3 D Spigel,4 A J. Wozniak,5 J Brahmer,6 P Kumar,7 S Fish,1 E. D Flick,1 S J. Hazard,1 TJ Lynch, Jr8, “Effectiveness of Bevacizumab Exposure Beyond Disease Progression in Patients With Non–Small Cell Lung Cancer: Analyses of the ARIES Observational Cohort Study” Submitted March 2015
6. Sachdev JC1 , Snider JN2, Allen JW1, Schwartzberg LS3, Young RR4, Javed AY5, Smeltzer MP6, Yunus F5, Verrier CS5, Jahanzeb M7. “Neoadjuvant Weekly nab-Paclitaxel Plus Carboplatin Followed by Doxorubicin Plus Cyclophosphamide With Bevacizumab Added Concurrently to Chemotherapy for Palpable and Operable Triple-Negative Invasive Breast Cancer” Submitted August 2014.
7. Wozniak AJ, Kosty MP, Jahanzeb M, Brahmer JR, Spigel D, Leon L, Fish S, Flick ED, Hazard SJ, Lynch Jr
TJ, “Clinical Outcomes in Elderly Patients with Advanced Non-Small Cell Lung Cancer: Results from ARIES, a Bevacizumab Observational Cohort Study” December 2014.
8. Tripathy D, Rugo H, Kaufman PA, Swain S, O’Shaughnessy J, Jahanzeb M, Mason G, Beattie M, Yoo B, Lai
C, Masaquel A, Hurvitz S: “The SystHERs registry: an observation cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer”, BMC Cancer 2014 May 2;14:307
9. Allen J, Moon J, Redman M, Gadgeel S, Kelly K, Mack P, Saba H, Mohamed M, Jahanzeb M, and David R Gandara. “SWOG S0802: A Randomized Phase II Trial of Weekly Topotecan with and without Ziv-aflibercept in Patients with Platinum-Treated Small Cell Lung Cancer” J Clin Oncol. 2014 Aug 10;32(23):2463-70
10. Aapro M, Andre F, Blackwell K, Calvo E, Jahanzeb M, Papazisis K, Porta C, Pritchard K, Ravaud A,
“Adverse Event Management in Patients With Advanced Cancer Receiving Oral Everolimus: Focus on Breast Cancer” Ann Oncol. 2014 Apr; 25(4):763-73.
11. Lynch TJ Jr, Brahmer J, Fischbach N, Garst J, Jahanzeb M, Kumar, P, Robles R, Spigel DR, Vidaver RM, Wozniak AJ, Fish S, Flick ED, Leon L, Datal D, Hazard SJ, Kosty MP; “Safety and Effectiveness of Bevacizumab - Containing Treatment for Non-Small Cell Lung Cancer: Final Results of the ARIES Observational Cohort Study” J Thorac Oncol. 2014 Sep;9(9):1332-9
Govindan, R, Grannis, Jr. FW, Horn L, Jahan TM, Jahanzeb M, Kessinger, A, Komaki R, Kong KF, Krs, MG, Krug LM, Lennes IT, Loo, Jr. BW, Martins R, O’Malley J, Osarogiabon RU, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood, DE, Yang SC, Hughes M, Gregory KM; “Non-Small Lung Cancer: “Clinical Practice Guidelines in Oncology”. J National Comprehensive Cancer Network 2012; 10:1236-1271
14. Abulkhair O, Saghi L, Saadedin A, Elzahwary H, Siddiqui N, Al Saleh M, Geara F, Birido N, Al-Eissa N, Sukhun SA, Abdulkareem H, Ayoub MM, Deirawan F, Fayaz S, Kandil A, Khatib S, El-Mistiri M, Salem D, Sayd ek SH, Jaloudi M, Jahanzeb M, Gradishar WI; MENA Breast Cancer Regional Guidelines Committee “Modification and Implementation of NCCN Guidelines on Breast Cancer in the Middle East and North Africa Region”. J Natl Compr Canc Netw. 2010 Jul; 8 Suppl 3:S8-S15.
Jahanzeb
06/15
54
15. Jazieh AR, Bamefleh H, Demirkazik A, Gaafar RM, Geara FB, Javaid M, Khader J, Omar W, Saadeddin A, Sabe HA, Shadmehr MB, El Sherif A, Uddin N, Jahanzeb M, Ettinger D; MENA Lung Cancer Regional Guidelines Committee “Modification and Implementation of NCCN Guidelines on Non-Small Cell Lung Cancer in the Middle East and North Africa Region. J Natl Compr Canc Netw. 2010 Jul; 8 Suppl 3:S16-21.
16. Johnson PE, Dahlman G, Eng K, Garg R, Gottlieb S, Hoffman JM, Howell P, Jahanzeb M, Johnson S,
Mackler E, Rubino M, Sarokhan B, Marc Stewart F, Tyler T, Vose, JM, Weinstein S, Li EC, Demartino J; NCCN Oncology Risk Evaluation and Mitigation Strategies (REMS) Work Group. J Natl Compr Canc Netw. 2010 Sep 8.
17. Jazieh A, Azim H, McClure J, Jahanzeb M “The Abu Dhabi Declaration: Adapted Application of NCCN
Clinical Practice Guidelines in Oncology in the Middle East and North Africa Region” Journal of the National. Comprehensive Cancer Network, 2010 Jul: Volume 8 Supplement 3.
18. Jazieh AR, Azim HA, McClure J, Jahanzeb M. “The process of NCCN Guidelines adaptation to the Middle
East and North Africa Region”. J Natl Compr Canc Netw. 2010; 8 Suppl 3:S5-7. 19. Abulkhair O, Saghir N, Sedky L, Saadedin A, Elzahwary H, Saddiqui N, Al Saleh M, Geara F, Birido N, Al
Eissa N, Sukhun SA, Abdulkareem H, Ayoub MM, Deirawan F, Fayaz S, Kandil A, Khatib S, El-Mistiri M, Salem D, Sayd el SH, Jaloudi M, Jahanzeb M, Gradishar WI; MENA Breast Cancer Regional Guidelines Committee. “Modification and Implementation of NCCN Guidelines on Breast Cancer in the Middle East and North African Region. J Natl Compr Canc Netw. 2010 Jul; 8 Suppl 3:S8-S15.
20. Jazieh AR, Azim HA, McClure J, Jahanzeb M, “The Process of NCCN Guidelines Adaptation to the Middle
East and North African Region” J Natl Compr Canc Netw. 2010 Jul; 8 Suppl 3:S5-7.
21. Jazieh AR, Bamefleh H, Demirkazik A, Gaafar RM, Javaid M, Khader J, Khodadad K, Omar W, Saadeddin A, Sabe HA, Shadmehr MB, El Sherif A, Uddin N, Jahanzeb M, Ettinger D,; MENA Lung Cancer Regional Guidelines Committee, “Modification and Implementation of NCCN Guidelines on Non-Small Lung Cancer in the Middle East and North Africa Region”. J National Comprehensive cancer Network. 2010; 8 Suppl 3:S16-
22. Johnson PE, Dahlman G, Eng K, Garg R, Gottlieb S, Hoffman J, Howell P, Jahanzeb M, et al, “NCCN
Oncology Risk Evaluation and Mitigation Strategies White Paper: “Recommendations for Stakeholders” Journal of the National Comprehensive Cancer Network, September 2010, Volume 8 Supplement 7.
23. Jazieh A, Azim H, McClure J, Jahanzeb M “The Abu Dhabi Declaration: Adapted Application of NCCN
Clinical Practice Guidelines in Oncology in the Middle East and North Africa Region” Journal of the National Comprehensive Cancer Network, 2010 Jul: Volume 8 Supplement 3.
24. Mahtani R, Jahanzeb M “Bisphosphonates as anticancer therapy for early breast cancer” Clinical Breast
Cancer. 2010 Oct 1; 10(5):359-66.
25. Ettinger D, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D’Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW Jr, JahanT, Jahanzeb M, et al, “Non-small cell lung cancer.” Journal of the National Comprehensive Cancer Network, 2010 Jul; 8(7):740-801.
26. Jahanzeb M, et al. “Bisphosphonates in lung cancer: more than a palliative therapy?” Seminars in Oncology.
2010 Jun; 37 Suppl 1:S45-52.
27. Sachdev JC, Ahmed S, Mirza MM, Farooq A, Kronish L, Jahanzeb M “Does race affect outcomes in triple negative breast cancer?” Breast Cancer. 2010 May 7; 4:23-33.
Jahanzeb
06/15
55
28. Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney R, Chirieac LR, D’Amico TA, Demmy TL, Govindan R, Grannis FW, Jahan T, Jahanzeb M, et al, “NCCN Clinical Practice Guidelines in Oncology, Non-Small Cell Lung Cancer” National Comprehensive Cancer Network 2010.
29. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Forero A,
Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, hudis CA, Jahanzeb M, et al, “NCCN Clinical Practice Guidelines in Oncology, Breast Cancer.” National Comprehensive Cancer Network 2010.
30. Jahanzeb, M, “Continuing trastuzumab beyond progression” Journal of Clinical Oncology. 2009 Apr 20;
27(12):1935-7.
31. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, hudis CA, Jahanzeb M, et al, “Breast Cancer Treatment Guidelines.” J Natl Compr Canc Netw. 2009 Feb; 7(2):122-92.
Grover TS, Haire W, Hassoun H, Hutchinson S, Jahanzeb M, et al, “Venous Thromboembolic Disease. NCCN. Clinical practice guidelines in oncology.” J Natl Compr Canc Netw. 2008 Sept; 6(8): 716-53.
33. Carlson R, Moench S, Hurria A, Balducci L, Burstein H, Goldstein L, Gradishar W, Hughes K, Jahanzeb M,
“NCCN Task Force Report: Breast Cancer in the Older Woman”, JNCCN, July 2008, Vol 6 No 4, p 1-27. 34. Ettinger D, Akerley W, Bepler G, Chang A, Cheney R, Chirieac L, D’Amico T, Demmy T, Feigenberg S, Figlin
R, Govindan R, Grannis Jr. F, Jahan T, Jahanzeb M, “Non-Small Cell Lung Cancer” JNCCN, March 2008, Vol 6 No 3, p 228-229, 251-269.
35. Gralow J, Rugo H, Gradishar W, O’Shaughnessy J, Jahanzeb M, et.al, “Novel Taxane Formulations in the Treatment of Breast Cancer: A Thought Leader Discussion and Consensus Roundtable”, Clinical Breast Cancer, Vol 8, No 1, Feb 2008, p 33-37.
36. Somerfield M, Jahanzeb M, et.al., “American Society of Clinical Oncology Guideline: Recommendations for
Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer”, Journal of Clinical Oncology, Vol 25 No 34; Dec 2007.
37. Hirsh V, Desjardins P, Needles B, Rigas J, Jahanzeb M, et.al., “Oral Versus Intravenous Administration of
Vinorelbine as a Single Agent for the First-Line Treatment of Metastatic Non-Small Cell Lung Carcinoma (NSCLX): A Randomized Phase II Trial” , Am J Clin Oncol. 2007 Jun; 30(3):245-51.
38. Limentani SA, Brufsky AM, Erban JK, Jahanzeb M, et al, “Phase II Study of Neoadjuvant
Docetaxel/Vinorelbine and Trastuzumab Followed by Surgery and Adjuvant Doxorubicin/Cyclophosphamide in Women with HER2-Overexpressing Locally Advanced Breast Cancer”, Journal of Clinical Oncology, Vol 25 No 10, April 2007.
39. Carlson R, Burstein H, Edge S, Goldstein L, Hayes D, Jahanzeb M, et.al., “Invasive Breast Cancer”, JNCCN
March 2007, Vol. 5 No. 3, p 246-312.
40. Limentani, SA, Brufsky, AM, Erban, JK, Jahanzeb, M, et.al., “Phase II Study of Neoadjuvant Docetaxel/Vinorelbine Followed by Surgery and Adjuvant Doxorubicin/Cyclophosphamide in Women With Stage IIB and III Breast Cancer”, Clinical Breast Cancer, Vol 6, No 6, Feb 2006:511-517.
Gradishar W, Hudis C, Jahanzeb M, et al, “HER2 Testing in Breast Cancer: NCCN Task Force Report and Recommendations”, JNCCN, Vol 4, Supp 3, July 2006.
44. Herbst R, Prager D, Hermann R, et.al. (Investigator – Jahanzeb M), “TRIBUTE: A Phase III Trial of Erlotinib
Hydrochloride (OSI-774) Combined with Carboplatin and Paclitaxel Chemotherapy in Advanced Non-Small Cell Lung Cancer”, J Clin Onc, Sept. 2005, Vol. 23 No. 25, p 5892-5899.
45. Gradishar WJ, Wedam SB, Jahanzeb M, et.al., “Neoadjuvant Docetaxel Followed by Adjuvant Doxoruicin
and Cyclophosphamide in Patients with State III Breast Cancer”, Ann Oncol. 2005; May 19, p2541. 46. Carlson RW, Anderson BO, Burstein HJ, Cox CE, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes
DF, Hudis C, Jahanzeb M, et.al., “Breast Cancer”, Journal National Comprehensive Cancer Network. 2005 May; 3(3):238-89.
47. Neuss, M, Desch, C, McNiff, K, Eisenberg, P, Gesme, D, Jacobson, J, Jahanzeb, M, et.al. “A Process for
Measuring the Quality of Cancer Care: The Quality Oncology Practice Initiative (QOPI)”, Journal of Clinical Oncology, 2005 Sept 1; 23(25):6233-9.
48. Muggia, FM, Carmichael, J, Winer, E, Jahanzeb, M., et.al., “Efficacy and Safety of Liposomal Anthracyclines
in Phase I/II Clinical Trials”, Seminars in Oncology, Dec 2004, Vol 31, No 6, suppl 13. 53-90 49. Jahanzeb, M, Sarna, G, Hirsch, R, Radice, P, Koletsky, A, et.al, “Docetaxel and Carboplatin as First-line
Therapy in Advanced Non-small Cell Lung Carcinoma: A Phase II Study, Anticancer Research, 2004; 24: 1239-1242.
50. Herbst R, Giaccone G, Schiller J, et.al., (Investigator – Jahanzeb M), “Gefitinib in Combination with Paclitaxel
and Carboplatin in Advanced Non-Small Cell Lung Cancer: A Phase III Trial – INTACT 2”, J of Clinical Oncology, Mar 2004, Vol. 22, No. 5, p 785-794.
51. International Adjuvant Lung Cancer Trial (IALT) Collaborative Group: “Cisplatin-Based Adjuvant
Chemotherapy in Patients with Completely Resected Non-Small Cell Lung Cancer”, (Investigator – Jahanzeb M) the New England Journal of Medicine, Vol. 350, No. 4, January 22, 2004; 351-360.
52. Kris M, Natale R, Herbst R, et.al., (Investigator – Jahanzeb M), “Efficacy of Gefitinib, an Inhibitor of the
Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients with Non-Small Cell Lung Cancer”, JAMA, Oct 22/29, 2003, Vol 290, No. 16, p 2149-2158.
53. Jahanzeb, M: “Trastuzumab-Based Combinations in Metastatic Breast Cancer: How to Make a Choice”,
Clinical Breast Cancer, Vol. 4, No. 1, April 2003; 28-38. 54. Semba C, Deitcher S, et al. (Investigator - Jahanzeb M) “Treatment of Occluded Central Venous Catheters
with Alteplase: Results in 1,064 Patients”, J Vasc Interv Radiol 2002; 13:1199-1205.
55. Jahanzeb M, Mortimer J, Yunus F, Irwin D, Speyer J, Koletsky A, Klein P, Sabir T, Kronish L: “Weekly Herceptin with Navelbine in Chemonaive Patients with HER2 Positive Metastatic Breast Cancer: A Phase II Multicenter Trial, Oncologist 2002;7 (5): 410-17
Jahanzeb
06/15
57
56. Deitcher S, Fesen M, et.al., (Investigator – Jahanzeb M) “Safety and Efficacy of Alteplase for Restoring
Function in Occluded Central Venous Catheters: Results of the Cardiovascular Thrombolytic to Open Occluded Lines Trail”, J of Clinical Oncology, Vol 20, Issue 1 (January), 2002 p 317-324.
57. Slamon DJ, Leyland-Jones B, Shak S, et.al., “Use of Chemotherapy plus a Monoclonal Antibody against
HER2 for Metastatic Breast Cancer That Overexpresses HER2”, New England Journal of Medicine, March 15, 2001, vol 344, no 11
58. Scheurle, D, Jahanzeb, M, Aronsohn, R, Watzek, L, and Narayanan, R. “HER-2/neu Expression in Archival
Non-Small Cell Lung Carcinomas Using FDA-Approved HercepTest”, Anticancer Research 2000 May-June; 20(3B): 2091-2096
Using Digital Differential Display, Cancer Research 60, 4037-4043, August 2000 60. McCarthy, M, Thompson A, Rivers, S, Jahanzeb, M: “The Benefits of Support Group Participation to Lung
Cancer Survivors”, Clinical Lung Cancer, Vol.1, No.2, 110-117, Nov. 1999 61. Jahanzeb M, Frankel C, Elkersh M., Koletsky A, Radice P, and Vogel C: “Rationale of Studying Doxil in
Metastatic Breast Cancer”. Oncology (suppl) 11:45-53, Oct, 1997 62. Graham MV, Jahanzeb M, Dresler JD, Cooper J, Emami B and Mortimer J: “Results of a Trial with
Topotecan Dose Escalation and Concurrent Thoracic Radiation Therapy for Locally Advanced, Inoperable Non-Small Cell Lung Cancer”, Int J Rad Oncol Biol Phys. 1996 Dec 1; vol 36, no. 5: 1215-1220
63. Jahanzeb M, Virgo KS, McKirgan LW and Johnson FE,: “Evaluation of Outcome by Race in Veterans with
64. Vokes EE, Rosenberg R, Jahanzeb M, Craig J, Gralla R, Belani C, Jones S, Purvis J and Hohneker J:
“Multicenter Study of Oral Navelbine in Previously Untreated Stage IV Non-Small Cell Lung Cancer (NSCLC)”. J Clinical Oncology 1995; 13:637-644.
65. Vokes EE, Rosenberg R, Jahanzeb M, Craig J, Gralla R, Belani C, Jones S, Bigley J and Hohneker J: “Oral
Vinorelbine (Navelbine) in the Treatment of Advanced Non-small Cell Lung Cancer: A Preliminary Report” Seminars in Oncology 1994; 21 ( 5), suppl. 10: 35-41.
Reviews
1. JC. Sachdev, MD, M Jahanzeb, “Use of Cytotoxic Chemotherapy in Metastatic Breast Cancer: Putting Taxanes in Perspective” Manuscript in preparation 2014
2. Aapro M, Andre F, Blackwell K, Calvo E, Jahanzeb M, Papazisis K, Porta C, Pritchard K, Ravaud A,
“Adverse Event Management in Patients With Advanced Cancer Receiving Oral Everolimus: Focus on Breast Cancer” Annals of Oncology 25:763-773, 2014
3. Sachdev J, Jahanzeb M, “Blockade of the HER family of Receptors in the Treatment of HER2-Positive
Metastatic Breast Cancer”. Clinical Breast Cancer, Vol. 12, No 1, 19-29
Jahanzeb
06/15
58
4. Mahtani R, Khan R, Jahanzeb M,” The Potential Application of Zoledronic Acid as Anticancer Therapy Patients with Non-Small Cell Lung Cancer” Clin Lung Cancer. 2011 Jan; 12 (1):26-32.
5. Mahtani R, Jahanzeb M, “Bisphosphonates as Anticancer Therapy for Early Breast Cancer”. Clinical
Breast Cancer, 2010 Oct 1; 10(5):359-66.
6. Jahanzeb M, et al. “Bisphosphonates in lung cancer: more than a palliative therapy?” Seminars in Oncology. 2010 June; 37 Suppl 1:S45-52.
7. Schreiber A, Sachdev J, Jahanzeb M, “Anastozole versus Exemestane in patients with postmenopausal breast cancer and visceral metastases” Clinical Medicine Reviews in Oncology 2010:2 79-87
8. Sachdev J, Jahanzeb M, “Evolution of Bevacizumab-Based Therapy in the Management of Breast
Cancer”, Clinical Breast Cancer, October 2008, Vol 8, No 5, p 402-410
9. Allen J, Jahanzeb M, “Extensive-Stage Small-Cell Lung Cancer: Evolution of Systemic Therapy and Future Directions”, Clinical Lung Cancer, September 2008, Vol 9, No 5, p 262-270
10. Jahanzeb M, “Adjuvant Trastuzumab Therapy for HER2-Positive Breast Cancer”, Clinical Breast Cancer,
August 2008, Vol 8, No 4, p 324-333
11. Allen J, Jahanzeb M, “Neoadjuvant Chemotherapy in Stage III Non-Small Cell Lung Cancer”, JNCCN, March 2008, Vol 6 No 3, p 285-292
12. Jahanzeb M, “Clinical Review: Trastuzumab: the foundation of care for HER2-positive breast cancer.” Am
J Hem/Onc. 2007; 6 (suppl 12):1-8.
13. Jahanzeb M, “Reducing Breast Cancer Recurrence after Tamoxifen in Postmenopausal Women with Hormone-Sensitive Breast Cancer”, Clinical Therapeutics, Clinical Therapeutics, Vol 29, No 8, Aug 2007, p 1535-1547.
14. Jahanzeb M, “Trastuzumab: The Foundation of Care for HER2-positive Breast Cancer”, Am J Hem Oncol,
2007;6 (suppl 12):1-8.
15. Jahanzeb M, Leyland-Jones B, “Management of a Patient with HER2-Overexpressing Infiltrating Ductal Carcinoma with Ductal Carcinoma In Situ”, Oncology Consultations, Vol 3, No 9, July 2006.
16. Jahanzeb M, “Management of deep vein thrombosis in cancer patients”, J Natl Compr Canc Netw. 2005
Nov; 3 Suppl 1:S50-3.
17. Jahanzeb M, Ihde DC: “Role of Adjuvant Therapy in Patients with Surgically Resected Non-Small Cell Lung Cancer” Cancer Control 1994 Oct;1(5):467-473.
Editorials / Monographs / Book Chapters / Case Reports
18. Jahanzeb M, “Continuing Trastuzumab Beyond Progression”, 2009 Journal of Clinical Oncology, Vol. 27, No 12 (April 20), 2009; pp.1935-1937
19. Raez L, Silva O, Jahanzeb M, “Lung Cancer: A Practical Guide”, 2008 Elsevier Limited, p. 111-123.
Jahanzeb
06/15
59
20. Jahanzeb M, Sachdev J, “HER2-Positive Early-Stage Breast Cancer: Decision-Making and Practical
Management”, Clinical Advances in Breast Cancer, January 2008, Vol 1, No. 1.
21. Sachdev J, Jahanzeb M, “Advances in the Treatment of Breast Cancer”, The Memphis Medical Society Quarterly, Fall 2007, Vol 10 No 3.
22. Sachdev J, Jahanzeb M, “A Patient with Bilateral Breast Cancer Treated with Neoadjuvant and Adjuvant
Trastuzumab”, Case Studies in Breast Cancer, Feb 2007, Vol. 5, No. 4.
23. Jahanzeb M, “Help Your Health Care Team Help You”, Caring4Cancer, Vol. 1, Issue 4, Spring 2007
24. Jahanzeb M, “Sexuality and Cancer”, Caring4Cancer, Vol.1, Issue 4, Spring 2007
25. Jahanzeb M, Galleshaw J, “How to Choose Therapy” Caring4Cancer, Issue 1, Vol 1, p 4, Spring 2006.
26. Jahanzeb M, Vogel C, “Adjuvant Chemotherapeutic Treatment of Node-Positive, Hormone-Negative Breast Cancer”, Oncology Consultations, Vol. 3, No. 3, Feb 2006.
27. Rosenthal, M, Jahanzeb M, “After Diagnosis of Non-Small Cell Lung Cancer, The Real Workup Begins”,
Hem/Onc Today, Vol 6, No.6, June 2005 p. 27.
28. Jahanzeb M, “An Overview of Anti-HER2 Therapy in Combination with Chemotherapy in Metastatic Breast Cancer”, Biological Therapy of Breast Cancer, Vol. 5, No. 3, Dec. 2004
29. Jahanzeb M, et.al., “Non-Small Cell Lung Cancer Clinical Practice Guidelines in Oncology”, Journal of
National Comprehensive Cancer Network, Vol. 2, Number 2, March 2004 (134).
30. Aslam R, Jahanzeb M, “A Patient With HER2 Positive Metastatic Breast Carcinoma Treated with Trastuzumab Based Therapy”, Physicians’ Education Resource, Aug. 2004, Vol 3 No 11.
31. Jahanzeb M, et.al., NCCN Lung Cancer Treatment Guidelines for Patients, Version II; JNCCN,
March/April 2004; Vol 2 No 2.
32. Jahanzeb M: “Treatment of HER2-Overexpressing Metastatic Breast Cancer with Chemotherapy and Anti-HER2 Monoclonal Antibody”, Human Epidermal Growth Factor Receptors in Oncology, Feb., 2004, Vol 1, No. 2: 6-8.
33. Jahanzeb M: “Advances with Trastuzumab/Chemotherapy in Metastatic Breast Cancer: Tidbits from
Texas (the 2002 San Antonio Breast Cancer Symposium)”, Cancer Abstracts and Summaries, April 2003, Vol.4., No.9.
34. Chantler ML, and Jahanzeb M, “Breast Cancer”, The Washington Manual of Oncology, Lippincott
Williams & Wilkins, 2002, 112-142.
35. Jahanzeb M, Sarna G, Hirsch R. “A Multicenter Phase II Study of Docetaxel and Carboplatin as First-Line Therapy in Advanced Non-Small Cell Lung Carcinoma” Cancer Conference Highlights, August, 2000
36. Jahanzeb M, “New Combinations Using Vinorelbine in the Management of Lung Cancer” Cancer
Conference Highlights, 8th World Conference on Lung Cancer , February 1998
37. Jahanzeb M, “Navelbine (Vinorelbine) for the Elderly Breast Cancer Patient” Navelbine: Emerging Data in
Jahanzeb
06/15
60
the Treatment of Solid Tumors, Monograph, February, 1998
38. Jahanzeb M and Ihde DC: “Chemotherapy of Lung Cancer” in Perry MC (ed) The Chemotherapy Source Book 2nd ed. Philadelphia, Williams & Wilkins 1995, 1103-1123
39. Jahanzeb M and Ihde DC: “Role of Adjuvant Chemotherapy in Surgically Resected Non-Small Cell Lung
Cancer” Cancer Control 1994; 1 ( 5): 467-473.
Partial Contributor / Expert Reviewer
1. Jahanzeb M, Yardley D, “Focus on Cytotoxic Therapy”, Recent Progress in Metastatic Breast Cancer, Physicians’ Education Resource, July 2013, pp1-12
2. Jahanzeb, M, “Breast Cancer: A Primer”
3. Jahanzeb, M, “Non-Small Cell Lung Cancer: Clinical Practice Guidelines in Oncology”, Journal National
Comprehensive Cancer Network, Mar 2008, Vol 6 No 3 p 228. 4. Jahanzeb M, “Management of Deep Vein Thrombosis in Cancer Patients”, Journal National
Comprehensive Cancer Network, 2005 Nov; 3(Suppl 1):S50-S53. 5. Jahanzeb M, “Potential use of Humanized Antibodies in the Treatment of Malignant Breast Cancer”,
Anticancer Therapy, Vol. 6 No. 7, July 2006, pp 1065-1074. 6. Jahanzeb M, “Sexuality and Cancer”, Caring4Cancer, Vol 1, Issue 4, Spring 2007 7. Jahanzeb M, The New Targeted Therapies: What You Should Know”, Caring4Cancer, Vol 1, Issue 4,
Spring 2007 8. Jahanzeb M, “Managing Side Effects of Cancer Treatments”, Caring4Cancer, Vol 1, Issue 4, Spring
2007
Abstracts
1. S Hurvitz, J O’Shaughnessy, G Mason, D Yardley, M Jahanzeb, A Brufsky, H Rugo, S Swain, P Kaufman, D Tripathy, M Mayer, S Ogale, B Yoo, M Beattie, M Cobleigh. “Central Nervous System Metastases at Diagnosis in Patients with HER2+ MBC: Baseline Characteristics, HER2-Targeted Treatments and Clinical Outcomes From the SystHERs Registry” SABCS Submitted June 2015 (Abstract #850696)
2. G.M Frampton, SM Ali, M Rosenzweig, J W Goldman, C B. Lee, J Weiss, J A. Bufill, R Salgia, M Jahanzeb, K Konduri, P M. Forde, D Morosini, J S. Ross, S-H I Ou, R Yelensky, V A. Miller, P J. Stephen, “Comprehensive genomic profiling (CGP) of advanced cancers to identify MET exon 14 alterations that confer sensitivity to MET inhibitors” Accepted ASCO 2015 (Abstract 11007) J Clin Oncol 33, 2015
3. G M. Frampton, S M. Ali, M Rosenzweig, J W. Goldman, C B. Lee, J Weiss, J A. Bufill, RSalgia,
MJahanzeb, K Konduri, P M. Forde, D Morosini, J S. Ross, Sai-Hong Ignatius Ou, R Yelensky, V A. Miller, P J. Stephens. “Comprehensive genomic profiling (CGP) of advanced cancers identifies MET exon 14 alterations that confer sensitivity to MET inhibitors” ASCO Submitted Feb 2015 (Abstract #153522)
4. M Pierobon, S Wong, A Reeder, S P Anthony, N J. Robert, D W. Northfelt, M Jahanzeb, L Vocila, J D
Jahanzeb
06/15
61
Wulfkuhle, B Dunetz, J Aldrich, S Byron, DW. Craig, L A. Liotta, E Petricoin III, J D. Carpten; “The AKT-mTOR pathway as a potential organ-specific drug target signature of hepatic metastases from breast cancer”. ASCO Submitted Feb 2015 (Abstract #151802)
5. D Tripathy1, A Brufsky2, M Cobleigh3, M Jahanzeb4, P Kaufman5, G Mason6, M Mayer7, J O’Shaughnessy8, H S. Rugo9, S M. Swain10, D A. Yardley11, M Beattie12, B Yoo12, S Hurvitz13 Increasing proportion of de novo compared with recurrent HER2-positive metastatic breast cancer: early results from the Systemic Therapies for HER2-Positive Metastatic Breast Cancer Registry Study. SABCS Feb 2015 Submitted (Poster P3-07-14)
6. Pierobon M.1, Anthony S.P.2, Reeder A.1, Robert N.3, Northfelt D.4, M. Jahanzeb.5, Vocila L.6, Wulfkuhle
J.1, Dunetz B.7, Liotta L. 1, Petricoin E.F. “Pathway Activation Mapping of Metastatic Breast Cancer Identifies Potential Organ-Specific Signatures: Implications for Patient Stratification to Targeted Treatment” Submitted SABCS 2014 (Poster P1-07-23)
7. Tripathy D, Brufsky A, Cobleigh M, Jahanzeb M, Kaufman P, Mason G, Mayer M, O’Shaughnessy J,
Rugo H, Swain SM, Yardley DA, Beattie M, Yoo B, Hurvitz S. “Increasing proportion of de novo compared with recurrent HER2-positive metastatic breast cancer: Early results from the systemic therapies for HER2-positive metastatic breast cancer registry study”. Abstract SABCS 2014 (Poster P3-07-14)
8. S Hurvitz, Jahanzeb M, P Kaufman, G Mason, M Mayer, H Rugo, D Tripathy, S Ogale, A Masaquel, B Yoo, M Beattie, M Cobleigh, “Patient reported outcomes (PROs) from the systemic therapies for HER2-positive metastatic breast cancer (MBC) registry study (SystHERs): eliciting the patient experience. Accepted 2014. (Abstract 286)
9. Pierobon M, Anthony SP, Reeder KA, Robert NJ, Northfelt DW, Jahanzeb M, Vocila L, Wulfkuhle JD,
Dunetz B, Liotta LA, Petricoin EF. Pathway activation mapping of metastatic breast cancer identifies potential organ-specific signatures: Implications for patient stratification to targeted treatment. (Abstract 1019)
10. L Leon, MP Kosty, Jahanzeb M, Spigel D, A Wozniak, Brahmer J, Kumar P, S Fish, Flick D. E, S Hazard J, Lynch, Jr. T, Effectiveness and Safety of Bevacizumab Exposure Beyond Disease Progressive in Patients With Non-Small Cell Lung Cancer: Analyses of the ARIES Observational Cohort Study. American Journal of Epidemiology. (Abstract 200)
11. Tripathy D1, Rugo HS, Kaufman PA, Swain S, O'Shaughnessy J, Jahanzeb M, Mason G, Beattie M, Yoo B, Lai C, Masaquel A, Hurvitz S., The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer”, 2014 May 2;14:307. doi: 10.1186/1471-2407-14-307
12. Tripathy D, Brufsky A, Cobleigh M, Jahanzeb M, Kaufman P, Mason G, Mayer M, O’Shaughnessy J, Rugo S. H, Swain. M S, Yardley A. D, Beattie M, Yoo B, Hurvitz S, “Increasing proportion of de novo compared with recurrent HER2-positive metastatic breast cancer: early results from the Systemic Therapies for HER2-Positive Metastatic Breast Cancer Registry Study”, SABCS 2014: Abstract
13. Hurvitz S, Jahanzeb M, P Kaufman, G Mason, M Mayer, H S. Rugo, D Tripathy, S Ogale, A Masaquel, B
Yoo, M Beattie, M A. Cobleigh Patient-Reported Outcomes (PROs) from the Systemic Therapies for HER2-Positive Metastatic Breast Cancer Registry Study (SystHERs): Eliciting the Patient Experience. Submitted Oct. 2014 (Abstract #137187)
14. Aapro M1, Andre F, Blackwell K, Calvo E, Jahanzeb M, Papazisis K, Porta C, Pritchard K, Ravaud A., “Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast
15. Maltzman JD, Fatato P, Hoffman K, Dougherty K, O’Shannessy D, Somers EB, Cobo M, Felip E, Jahanzeb M; Morphotek, Exton, PA; “Phase 2 Double-Blind, Placebo-Controlled Doublet in Subjects with Previously Untreated Folate Receptor Alpa (FRA) Expressing Non Small Cell Lung Cancer (NSCLC)”. Poster presentation IASLC 2013
16. Snider JN, Sachdev JC, Allen JW, Schwartzberg LS, Young RR, Javed AY, Yunus F, Verrier CS, Jahanzeb M; “High pathologic complete response (pCR) with weekly nanoparticle albumin bound (nab-P) + carboplatin (C) followed by doxorubicin plus cyclophoshamide (AC) with concurrent bevacizumab (B) for triple negative breast cancer (TNBC)”. Proceedings of ASCO 2013 Abst # 1068
17. KL Obholz, KL Blackwell, S Glück, Jahanzeb M, KD Miller, NJ Robert, AD Bowser, J Mortimer, and RW
Carlson, Clinical impact of internet-based tools to help guide therapeutic decisions for metastatic breast cancer (MBC) Cancer Res December 15, 2013 73; Abstract P1-12-01 (Poster presentation SABCS 2013)
18. Snider JN, Allen JW, Young R, Schwartzberg L, Javed Y, Jahanzeb M, Sachdev JC, “Neoadjuvant
bevacizumab with weekly nanoparticle albumin bound (nab)-paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide (AC) for triple negative breast cancer” SABCS December 15, 2012; Volume 72, Issue 24, Supplement 3 (Posters)
19. Ettinger D, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D’Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW Jr, JahanT, Jahanzeb M, et al, “Non-small cell lung cancer.” J Natl Compr Canc Netw. 2012 Oct 1;10(10):1236-71.
20. Snider, J Young R, Schwartzberg, L, Jahanzeb M, and Sachdev J Neoadjuvant bevacizumab with weekly nab-paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide (AC) for triple-negative breast cancer. PASCO 2012 Abst # TPS1137
21. Lynch TJ, Jahanzeb M, Spigel D, Wozniak AJ, Leon L, Fish S, Flick ED, Dalal D, Kosfy MP, “Cumulative
Exposure to Bevacizumab (BV) after Disease Progression (PD) Correlates with Survival in Non-Small Cell Lung Cancer (NSCLC)”:, a time-dependent analysis of the ARIES observation cohort study. Journal/Congress: ESMO 2012. Accepted for Poster Presentation
22. Snider JN, Young RR, Schwartzberg LS, Allen, JW Javed, YA, Jahanzeb M, Sachdev JC; “Neoadjuvant
Bevacizumab with Weekly Nab-Paclitaxel + Carboplatin followed by Doxorubicin + Cyclophosphamide (AC) for Triple Negative Breast Cancer”. Proceedings of American Society of Clinical Oncology, Submitted 2012.
23. Arteaga CL, Mayer IA, O’Neill AM, Swaby RF, Alpaugh RK, Yang XJ, Wagner LI, Meropol NJ, Saphner TJ, Jahanzeb M, Perez EA, Lin NU, Sledge GW; “A Randomized Phase III Double-Blinded Placebo-Controlled Trial of First-Line Chemotherapy and Trastuzumab with or without Bevacizumab for Patients with HER2/neu-overexpressing Metastatic Breast Cancer (HER2+ MBC): A Trial of the Eastern Cooperative Oncology Group (E1105). Proceedings of American Society of Clinical Oncology. Submitted 2012.
24. Wozniak A, Jahanzeb M, Lynch T, “Cumulative Exposure to Bevacizumab (BV) After Induction Therapy (tx) Correlates with Increased Survival in Patients (pts) with Non-small Cell Lung Cancer (NSCLC)”, Stockholm Congress, September 2011, ECCO/ESMO Poster Presentation, Poster # 079
25. Brahmer J, Jahanzeb M, Priya K, Robles R, Wozniak A, Lynch T, “Use of Bevacizumab (BV) After Induction Therapy is Associated with Survival Benefit in Patients (pts) with Non-small Cell Lung Cancer
(NSCLC) in the ARIES Observational Cohort Study (OCS)”, Stockholm Congress, September 2011, ECCO/ESMO Poster Presentation, Poster # 009.
26. Kosty M, Jahanzeb M, Garst J, Spigel D, Leon L, Wendlberger S, Schnurr J, Photowala H, “Clinical Outcomes for Bevacizumab (BV)-treated Elderly Patients with Non-small Cell Lung Cancer (NSCLC): Results from the ARIES Observational Cohort Study (OCS)”, Stockholm Congress, September 2011, ECCO/ESMO Poster Presentation, Poster # 062.
27. Sachdev JC, Kronish LE, West S, Schwartzberg L, Jahanzeb M, “Neoadjuvant bevacizumab with weekly
nanoparticle albumin bound (nab)-paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide (AC) for triple negative breast cancer” ASCO 2010 abstract# TPS100 December 15, 2012; Volume 72, Issue 24, Supplement 3
28. Wozniak A, Garst J, Jahanzeb M, Kosty MP, Vidaver R, Beatty S, Teng SL, Flick ED, Sing A, Lynch T for
the ARIES Investigators “Preliminary clinical outcomes (CO) for advanced non-small cell lung cancer (NSCLC) patients (pts) from ARIES, a bevacizumab (BV) treatment observational cohort study (OCS)” ASCO 2010 abstract# 7618
29. Brahmer J, Spigel D, Garst JL, Jahanzeb M, et al “Preliminary effectiveness outcomes by tumor
histology in advanced non-small-cell lung cancer (NSCLC) patients(pts): Results from ARIES, a bevacizumab (BV) observational cohort study (OCS), ESMO 2010
30. Kosty M, Kumar P, Wozniak A, Jahanzeb M, Chung C, Wang L, Sing A, Lynch T, “Development of
Cavitation While on Bevacizumab (BV) Therapy in Patients (Pts) with Non-Small Cell Lung Cancer (NSCLC): Results from ARIES – a Bevacizumab (BV) Treatment Observational Cohort Study (OCS)”, submitted – December 2008
31. Sachdev J, Kronish L, Cohen N, Havlin K, Levine E, Jahanzeb M, “A multicenter phase II trial of
carboplatin, vinorelbine and trastuzumab in previously untreated patients with HER-2 positive metastatic breast cancer”, submitted to Breast Cancer Symposium
32. Lynch T, Jahanzeb M, et.al, “Clinical Outcomes for Non-Small Cell Lung Cancer (NSCLC) from the
ARIES Study: a Bevacizumab (BV) Treatment Observational Cohort Study (OCS), Abstract # 239P (Poster Presentation) ESMO 2008.
33. McFarlane J, Liman A, Jahanzeb M. “Contribution of positive renal vein margin to relapse risk in renal
cell cancer”. Submitted to ASCO 2008 34. Azmi S, Sachdev J, Kronish L, Jahanzeb M, Smeltzer M, “Hypersensitivity of Cetuximab: Is there an
Association with Race, Region or both?” ASCO 2008 35. Paba C, Sachdev J, Kronish L, Jahanzeb M, Waheed S. “Empiric dose reduction of Pegfilgrastim in
breast cancer patients receiving cytotoxic chemotherapy”. ASCO 2008 36. Franz, G, Kronish L, Osarogiagbon R, Thompson L, Jahanzeb M, “Patterns of PET/CT scan use in
patients with advanced Non Small Cell Lung Cancer (NSCLC)”. ASCO 2008. 37. Schreiber, A, Jahanzeb M, Kronish L, “Serial measurements of quality measures using the quality
oncology practice initiative (QOPI) by oncology trainees (fellows) at a single institution”. ASCO 2008. 38. Jahanzeb M. “Reducing the Risk for Breast Cancer Recurrence after Completion of Tamoxifen
Treatment in Postmenopausal Women”. Clinical Therapeutics, vol. 29 number 8, pgs 1535 – 1547.
Jahanzeb
06/15
64
August 2007. 39. Sachdev J, Jahanzeb M, A multicenter phase II trial of carboplatin, vinorelbine, and trastuzumab in
previously untreated patients with HER2 positive metastatic breast cancer. SABCS, Dec. 2007. 40. Waheed S, Jahanzeb M, Empiric dose reduction of pegfilgrastin in breast cancer patients receiving
cytotoxic chemotherapy. SABCS, Dec. 2007. 41. Jahanzeb M, Limentani SA, et.al.: Dose dense neoadjuvant treatment of women with breast cancer
utilizing docetaxel, vinorelbine and trastuzumab with growth factor support, Selected for poster presentation at American Society of Clinical Oncology Annual Meeting, 2005 (Abst #591)
42. Desch CE, Eisenberg D, Gesme D, Jacobson J, Jahanzeb M, et.al.: A practice-based, voluntary program
for promoting excellence in cancer care: A Pilot study of feasibility, cost and preliminary results, American Society of Clinical Oncology Annual Meeting, 2004 (Abst #6029) 43. Limentani SA, Brufsky AM, Erban JK, Jahanzeb M, Lewis D: Dose dense neoadjuvant treatment of
women with breast cancer utilizing docetaxel and vinorelbine with growth factor supplements, San Antonio Breast Cancer Symposium, December, 2003 (Abst #251)
44. Limentani SA, Brufsky AM, Erban JK, Jahanzeb M, Lewis D: Dose dense neoadjuvant treatment of
women with breast cancer utilizing docetaxel, vinorelbine and trasturzumab with growth factor support, San Antonio Breast Cancer Symposium, December, 2003 (Abst #240)
W.J., National Cancer Institute, Bethesda, MD: Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide for stage III breast cancer: Clinical response and long-tern survival, American Society of Clinical Oncology, June, 2003 (Abst #143)
46. Limentani, S.A., Brufsky, A.M., John, E., Jahanzeb, M, Lewis, D., Carolinas Hem-Onc Associates and the
Blumenthal Cancer Center, Charlotte, NC: Dose dense neoadjuvant treatment of women with beast cancer utilizing docetaxel and vinorelbine with growth factor support, American Society of Clinical Oncology, June, 2003 (Abst #131)
47. Dragnev, K.H., Clamon, G., Raez, L. Jahanzeb, M., et.al., Docetaxel and cisplatin as induction therapy
for stage IIIA (N2) non-small cell lung cancer (NSCLC), American Society of Clinical Oncology, June, 2003 (Abst #2652)
48. Peyton, J.D., Flax, S., Jahanzeb M,: Low utility of bone marrow biopsy and aspirate for ruling out
malignancy as a cause for FUO in HIV patients, American Society of Clinical Oncology, June, 2003 (Abst #3580)
49. Limentani , SA, Brufsky, AM, Erban, J, Jahanzeb M, Lewis, D., Carolinas Hem-Onc Association and the
Blumenthal Cancer Center, Charlotte, NC, University of Pittsburgh Cancer Institute, Magee-Women’s Hospital, Pittsburgh, PA, Tufts-New England Medical Center, Boston, MA, University of Tennessee College of Medicine, Memphis, TN: Dose dense neoadjuvant treatment of women with breast cancer utilizing docetaxel, vinorelbine and trastuzumab with growth factor support, San Antonio Breast Cancer Symposium, 2002.
50. Limentani, SA, Brufsky, AM, Erban, J, Jahanzeb M, Lewis, D, Carolinas Hem-Onc Association and the
Blumenthal Cancer Center, Charlotte, NC, University of Pittsburgh Cancer Institute, Magee-Women’s Hospital, Pittsburgh, PA, Tufts-New England Medical Center, Boston, MA, University of Tennessee
Jahanzeb
06/15
65
College of Medicine, Memphis, TN: Dose dense neoadjuvant treatment of women with breast cancer utilizing docetaxel and vinorelbine with growth factor support, San Antonio Breast Cancer Symposium, 2002 (Abst #162)
51. Natale R, Skarin A, Maddox A, Hammond L, Thomas R, Gandara D, Gerstein H, Panella T, Cole J,
Jahanzeb M, Kash J, Hamm J, Langer C, Saleh M, Stella P, Heyes A, Helms L, Ochs J, Wolf M, Kay A: Improvement in Symptoms and Quality of Life (QOL) for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving ZD 1839 (‘IRESSA’) in Ideal 2, American Society of Clinical Oncology, May, 2002 (Abst #1167)
52. Limentani, SA, Jahanzeb M, O’Leary P, Lewis D, Kronish, L: Neoadjuvant Treatment of Women With
Breast Cancer Utilizing Docetaxel and Vinorelbine With Growth Factor Support, Proceedings of ASCO, 2002 (abst #1939)
53. Jahanzeb M, Mortimer, J, Yunus F, Irwin D, Speyer J, Koletsky A, Klein P, Sabir T, Kronish L: Phase II
Trial of Weekly Vinorelbine and Trastuzumab as First-Line Therapy in Patients with HER2+ Metastatic
Breast Cancer. The Oncologist 2002, 7:410-417.
54. Treat J, Huang C, Damanjov N, Jahanzeb M, Edelman M, Koehler M: ZD0473 Phase II Monotherapy Trial in Second-Line Non-Small Cell Lung Cancer, European Journal of Cancer, Vol 37. Suppl. 6, October 2001 (Abst #209)
55. Jahanzeb M, Mortimer J, Yunus F, Irwin D, Speyer J, Koletsky A, Klein P, Sabir, T Kronish L: A Phase II
Multicenter Trial of Weekly Herceptin with Navelbine in Chemonaive Patients with HER2 Positive Metastatic Breast Cancer, European Cancer Conference (ECCO), Lisbon, Oct 2001, Poster presentation
56. Jahanzeb M, Mortimer, J, Yunus F, Irwin D, Speyer J, Koletsky A, Klein P, Sabir T, Kronish L: Multicenter
Phase II Trial of Weekly Vinorelbine plus Herceptin in Chemonaive Patients with Her-2/neu Positive Metastatic Breast Carcinoma, Proceedings of American Society
57. Jahanzeb M, Sarna G, Hirsch R, Radice R, Koletsky A, Martinez M, Kruglyak E, Wolin E, Comacho E,
Kronish L, And Byrne, C: Carboplatin (C) and docetaxel (D) in Previously Untreated Advanced Non-Small Cell Lung Carcinoma (NSCLC): A Multicenter Phase II Trial, International Association for the Study of Lung Cancer (IASLC) 9th World Conference on Lung Cancer, Sept 2000 (oral presentation)
58. Jahanzeb M, Sarna G, Hirsch R, Radice P, Koletsky A, Martinez M, Kruglyak E, Wolin E, Comacho E,
Pearce P, Byrne C, and Frankel C: A Multicenter Phase II Trial of Carboplatin (C) and Docetaxel (D) in Previously Untreated Advanced Non-Small Cell Lung Carcinoma (NSCLC), Proceedings of American Society of Clinical Oncology, May 2000, (Abst #2011)
59. Scheurle D, Jahanzeb M, Aronsohn R, Watzek L, and Narayanan R: HERs/neu Expression in Archival
Non-Small Cell Lung Carinomas (NSCLC) Using FDA Approved Hercep test and Clinical Correlation, Proceedings of American Society of Clinical Oncology, May, 2000 (Abst 2012)
60. Jahanzeb M, Greenhawt M, Koletsky A, Frankel C, Pearce P, Byrne C: A Phase I Trial of Gemcitabine
and Vinorelbine in Relatively Elderly Patients with Refractory Solid Tumors, Poster Presentation, U S Gemzar Investigators Meeting, New Orleans, March, 1999
61. Jahanzeb M, Hirsch R, Marrs N, Sharpington T: Phase I Study of Doxil in Combination with Escalating
Doses of Navelbine for the Treatment of Patients with Advanced Malignancies., Proceedings of American Society of Clinical Oncology , May 1999 (Abst #827)
Jahanzeb
06/15
66
62. Hirsch R, Jahanzeb M, Marrs N., Sharpington, T: Phase I Study of Doxil in Combination with Escalating Doses of Taxotere for the Treatment of Patients with Advanced Malignancies., Proceedings of American Society of Clinical Oncology , May 1999 (Abst #820)
63. Radice P, Koletsky A, Jahanzeb M, Gomez E, Kruglyak E, Hirsch R, Cecchi G, Martinez M, Irwin D,
Lemon R, Tracy M, Pearce P, Byrne C, Frankel C: Weekly Peglyated Liposomal Doxorubicin (PEG-LD) is Extremely Well Tolerated as Second Line Chemotherapy, Proceedings of American Society of Clinical Oncology, May 1999 (Abst #2004)
64. Koletsky A, Jahanzeb M, Radice P, Berliner A, Gomez E, Kruglyak E, Hirsch R, Cecchi G, Martinez M,
Irwin D, Lemon R, Tracy M, Byrne C, Frankel C: Peglyated Liposomal Doxorubicin (PEG-LD) as Second Line Treatment of Advanced Non-Small Cell Carcinoma (NSCLC) After Platinum Based Therapy: A Randomized Phase II Trial, Proceedings of American Society of Clinical Oncology, May, 1999 (Abst #1976)
65. Greenhawt M, Jahanzeb M, Koletsky A, Frankel C, Pearce P, Bryne C: A Phase I Trial of Vinorelbine
and Gemcitabine in Relatively Elderly Patients with Refractory Solid Tumors, Proceedings of American Society of Clinical Oncology, May 1999 (Abst #897A)
66. Jahanzeb M, Koletsky A, Greenhawt M, Frankel C, Byrne C: A Phase I Trial of Gemcitabine and
Vinorelbine Employing Planned Half Doses on Day 8 in Patients with Refractory Solid Tumors, Poster Presentation, Gemzar Investigators Meeting, Memphis, TN, March, 1998
67. Koletsky A, Jahanzeb M, Radice P, Gomez E, Kruglyak E, Hirsch R, Cecchi G, Martinez M, Irwin D,
Lemon R, Tracy M, Frankel C, Byrne C: A Randomized Phase II Trial of Pegylated Liposomal Doxorubicin (PEG-LD) as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients with Prior Exposure to Platinum Based Therapy, Proceedings of American Society of Clinical Oncology, May, 1998 (Abstract #1888)
68. Jahanzeb M, Frankel C, Elkersh M, Koletsky A, Radice P, and Vogel C: Activity and Favorable Toxicity of
Stealth Liposomal Doxorubicin (Doxil) in a Population of Heavily Pretreated Patients with Solid Tumors. UICC Oral Presentation, First International meeting of Advances in the Knowledge of Cancer Management, June 28 to July 1, 1997, Vienna Austria (Abst #160)
69. Jahanzeb M, Vogel C, Elkirsh M, Koletsky A, Radice P, and Frankel C: Stealth Liposomal Doxorubicin
(Doxil) Causes a Mild and Delayed Leukopenia Compared to Standard Doxorubicin in Patients with Solid Tumors. Proceedings of American Society of Clinical Oncology, May 1997 (Abst # 843)
70. Jahanzeb M, Virgo KS, McKirgan LW and Johnson FE: Evaluation Of Outcome by Race In Veterans with
Early-Stage Non-Small Cell Lung Cancer (NSCLC) (selected for poster presentation at the 1995 annual meeting of ASCO) (Abst #442)
71. Vokes EE, Rosenberg R, Jahanzeb M, Craig J, Gralla R, Belani C, Jones S, Purvis J and Hohneker J:
Multicenter Study of Oral Navelbine in Previously Untreated Stage IV Non-Small Cell Lung Cancer (NSCLC). Proceedings of 7th World Lung Cancer Conference, June 1994 (Abst # 465)
72. Graham MV, Jahanzeb M, Dresler C, Cooper J, Emami B and Mortimer J: Preliminary results of a Phase
I study of Topotecan plus thoracic radiotherapy for locally advanced Non-Small Cell Lung Cancer Proceedings of American Society of Clinical Oncology, May, 1994 (Abstract # 1132)
73. Vokes EE, Rosenberg R, Jahanzeb M, Craig J, Gralla R, Belani C, Jones S, Purvis J and Hohneker J:
Multicenter Study of Oral Navelbine in Previously Untreated Stage IV Non-Small Cell Lung Cancer
Jahanzeb
06/15
67
(NSCLC). Proceedings of American Society of Clinical Oncology, May, 1993 (Abstract # 1120) 74. Jahanzeb M, Zutter M, Loeb V and Mortimer J: Castleman's Disease: Recent Experience at Washington
University. Proceedings of American Society of Clinical Oncology, May, 1992 (Abstract 154)
75. Pierobon M, Anthony SP, Reeder A, Nicholas Robert, D. Northfelt, M Jahanzeb, Vocila L, Wulfkuhle J, Dunetz B, Liotta L, Petricoin E. F. Pathway activation mapping metastatic breast cancer identifies potential organ-specific signatures: implications for patient stratification to targeted treatment
